Introduction {#Sec1}
============

Vaccine development was considered as the most important subjects to protect from a highly infectious disease especially when treatment is not available; nowadays, a new way for vaccine design was done by a new aspects called immune-informatics that depends on software program to determine the most immunogenic parts of the organisms (epitopes) like these software that were used in this study to try to develop more powerful immunogenic MERS-CoV vaccine because the previous MERS-CoV vaccine can be either inactivated coronavirus, live attenuated coronavirus, S protein-based, DNA vaccines, and combination vaccines against coronaviruses; as we know coronaviruses were first described in the 1960s from the nasal cavities of patients with common cold. These strains of coronaviruses were called HC-229E and HC-OC43; in 2003, following the outbreak of severe acute respiratory syndrome (SARS) that resulted in over 8000 infections, about 10% of which resulted in death, but in 24 September 2012, a first report of isolated new novel coronavirus like SARS-CoV by Egyptian virologist Dr. Ali Mohamed Zaki in Jeddah, Saudi Arabia, from the lungs of a 60-year-old male patient with acute pneumonia and acute renal failure becomes a new discovery that was recently called MERS-CoV; this finding was posted on ProMED-mail \[[@CR1]--[@CR3]\]. MERS-CoV belong to group C β-coronaviruses that characterize 30 KB genome, ssRNA virus, positive sense with 10 predicting open reading frames (ORFs) like E, M, S, enveloped. MERS-CoV can grow in a culture media; the genome size, organization, and sequence analysis revealed that the NCoV is most closely related to bat coronaviruses BtCoV-HKU4 and BtCoV-HKU5; a partial spike gene sequencing of South African Neoromicia bats was considered as close relative to MERS-Cov as illustrated by nucleotide percentage distance substitution model and the complete deletion option in MEGA; this makes the possibility of a common coronavirus vaccine more desirable \[[@CR3]--[@CR5]\].

This study depended on using S and E with modified S and E protein sequences through in silico approach to develop MERS-CoV vaccine in addition to study the side effects of mutation in those selected sequences on vaccine development. Spike glycoprotein is characterized by a trimeric, envelope-anchored, type I fusion glycoprotein that interfaces with human dipeptidyl peptidase 4 (DPP4) receptor; to mediate viral entry, it is composed of 2 subunits; they are S1, which contains the receptor-binding domain and determines cell tropism, and S2, the location of the cell fusion machinery, while E protein was considered as part of virus cell membrane \[[@CR4], [@CR6]\].

This study showed that S, E and their modified sequences can be considered safe and most promising MERS-CoV vaccine without any kinds of allergic reactions.

Materials and Methods {#Sec2}
=====================

Protein Sequence Retrieval {#Sec3}
--------------------------

A total number of 130 spike (S) glycoproteins and 41 envelope (E) proteins of MERS-CoV were retrieved from NCBI (<http://www.ncbi.nlm.nih.gov/protein/>) database in September 2016, which was actually collected from different parts of the world, such as Saudi Arabia, China, Thailand, United Kingdom, Qatar, Tunisia, and South Africa. The accession numbers of retrieved strains were listed in Supplementary Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. All methods below were applied for S, E, modified S & E proteins; modified S and E proteins were made by randomly changing some amino acids in their reference sequences; *see* Table [1](#Tab1){ref-type="table"} envelope protein (E) with Table [2](#Tab2){ref-type="table"} spike glycoprotein (S) gene bank accession numbers.Table 1Gene Bank Accession No of Envelope proteinAccession No of E proteinDate and place of collectionType of specimenYP_009047209.113-Jun-2012AKJ80142.127-May-2015/ChinaNasopharyngeal swabAIZ74456.107-May-2013/FranceSputum on Vero E6AIZ74443.107-May-2013/FranceInduced sputumAIZ74434.107-May-2013/FranceInduced sputumAIZ74422.126-Apr-2013/FranceBroncho-alveolar lavageAIZ74406.126-Apr-2013/FranceBroncho-alveolar lavageAID50423.110-Feb-2013/United KingdomThroat swabAID50423.110-Feb-2013/United KingdomThroat swabALD51909.117-Jun-2015/ThailandSputumAMQ49075.124-Aug-2015/Saudi ArabiaRespiratory secretionsAMQ49064.127-Aug-2015/Saudi ArabiaRespiratory secretionsAMQ49053.124-Aug-2015/Saudi ArabiaRespiratory secretionsAMQ49020.112-Jul-2015/Saudi ArabiaRespiratory secretionsAMQ49042.124-Aug-2015/Saudi ArabiaRespiratory secretionsAMQ49031.124-Aug-2015/Saudi ArabiaRespiratory secretionsALW82736.102-Feb-2015/Saudi ArabiaALW82714.105-Feb-2015/Saudi ArabiaRespiratory secretionsALW82758.110-Feb-2015/Saudi ArabiaRespiratory secretionsALW82747.113-Feb-2015/Saudi ArabiaRespiratory secretionsALW82696.115-Feb-2015/Saudi ArabiaRespiratory secretionsALW82685.107-Feb-2015/Saudi ArabiaRespiratory secretionsALW82674.127-Mar-2015/Saudi ArabiaRespiratory secretionsAFY13312.111-Sep-2012/United KingdomAIG13101.12011/South AfricaAHY21474.1Mammalian cell line Vero CCL81AHY22569.1Nov-2013/Saudi Arabianasal swab (camel)AHB33331.107-May-2013/FranceVero E6 isolate/sputumAHC74092.113-Oct-2013/QatarAHC74103.117-Oct-2013/QatarAHI48522.102-May-2013/Saudi ArabiaAHI48566.105-Aug-2013/Saudi ArabiaAHI48544.128-Aug-2013/Saudi ArabiaAHI48533.117-Jul-2013/Saudi ArabiaAHI48555.112-Jun-2013/Saudi ArabiaAHI48588.102-Jul-2013/Saudi ArabiaAHI48577.115-Aug-2013/Saudi ArabiaAHI48599.112-Jun-2013/Saudi ArabiaAHI48610.101-Mar-2013/Saudi ArabiaTable 2Gene Bank Accession No of S glycoproteinAccession No of S glycoproteinDate and place of collectionType of specimenYP_009047204.113-Jun-2012AHX00721.130-Dec-2013/Saudi ArabiaCamelAHX00711.130-Dec-2013/Saudi ArabiaDromedaryAHX00731.130-Nov-2013/Saudi ArabiaDromedaryAHZ90568.108-May-2013/TunisiaSerumAHX71946.116-Feb-2014/QatarCamelus dromedariesALJ54521.112-May-2015/Saudi ArabiaRespiratory secretionsALJ54520.113-Jun-2015/Saudi ArabiaRespiratory secretionsALJ54519.107-Jun-2015/Saudi ArabiaRespiratory secretionsALJ54518.104-Jun-2015/Saudi ArabiaRespiratory secretionsALJ54517.103-Jun-2015/Saudi ArabiaRespiratory secretionsALJ54516.102-Jun-2015/Saudi ArabiaRespiratory secretionsALJ54515.101-Jun-2015/Saudi ArabiaRespiratory secretionsALJ54514.129-May-2015/Saudi ArabiaRespiratory secretionsALJ54513.125-Apr-2015/Saudi ArabiaRespiratory secretionsALJ54512.127-May-2015/Saudi ArabiaRespiratory secretionsALJ54511.127-May-2015/Saudi ArabiaRespiratory secretionsALJ54510.128-May-2015/Saudi ArabiaRespiratory secretionsALJ54509.128-May-2015/Saudi ArabiaRespiratory secretionsALJ54508.129-May-2015/Saudi ArabiaRespiratory secretionsALJ54507.129-May-2015/Saudi ArabiaRespiratory secretionsALJ54506.123-May-2015/Saudi ArabiaRespiratory secretionsALJ54505.122-May-2015/Saudi ArabiaRespiratory secretionsALJ54504.120-May-2015/Saudi ArabiaRrespiratory secretionsALJ54503.117-May-2015/Saudi ArabiaRespiratory secretionsALJ54502.112-May-2015/Saudi ArabiaRespiratory secretionsALJ54501.121-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54500.110-May-2015/Saudi ArabiaRespiratory secretionsALJ54499.109-May-2015/Saudi ArabiaRespiratory secretionsALJ54498.109-May-2015/Saudi ArabiaRespiratory secretionsALJ54497.109-May-2015/Saudi ArabiaRespiratory secretionsALJ54496.116-Apr-2015/Saudi ArabiaRespiratory secretionsALJ54495.113-Apr-2015/Saudi ArabiaRespiratory secretionsALJ54494.104-Apr-2015/Saudi ArabiaRespiratory secretionsALJ54493.104-Apr-2015/Saudi ArabiaRespiratory secretionsALJ54492.130-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54491.125-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54490.124-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54489.108-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54488.104-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54487.104-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54486.128-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54485.125-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54484.114-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54483.113-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54482.113-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54481.113-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54480.110-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54479.101-Apr-2015/Saudi ArabiaRespiratory secretionsALJ54478.129-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54477.129-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54476.121-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54475.120-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54474.109-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54473.105-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54472.101-May-2015/Saudi ArabiaRespiratory secretionsALJ54471.108-May-2015/Saudi ArabiaRespiratory secretionsALJ54470.110-May-2015/Saudi ArabiaRespiratory secretionsAID55078.12014/Saudi ArabiaAID55077.12014/Saudi ArabiaAID55076.12014/Saudi ArabiaAID55075.12014/Saudi ArabiaAID55074.12014/Saudi ArabiaAID55073.122-Apr-2014/Saudi ArabiaAID55072.115-Apr-2014/Saudi ArabiaAID55071.121-Apr-2014/Saudi ArabiaAID55070.114-Apr-2014/Saudi ArabiaAID55069.112-Apr-2014/Saudi ArabiaAID55068.107-Apr-2014/Saudi ArabiaAID55067.12014/Saudi ArabiaAID55066.12014/Saudi ArabiaALJ54469.113-May-2015/Saudi ArabiaRespiratory secretionsALJ54468.110-May-2015/Saudi ArabiaRespiratory secretionsALJ54467.112-May-2015/Saudi ArabiaRespiratory secretionsALJ54466.112-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54465.107-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54464.108-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54463.101-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54462.1Saudi ArabiaRespiratory secretionsALJ54461.110-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54460.121-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54459.121-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54458.123-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54457.123-Feb-2015/Saudi ArabiaRespiratory secretionsAID55098.12014/Saudi ArabiaAID55097.12014/Saudi ArabiaAID55096.12014/Saudi ArabiaAID55095.12014/Saudi ArabiaAID55094.12014/Saudi ArabiaAID55093.12014/Saudi ArabiaAID55092.12014/Saudi ArabiaAID55091.12014/Saudi ArabiaAID55090.12014/Saudi ArabiaAID55089.12014/Saudi ArabiaAID55088.12014/Saudi ArabiaAID55087.12014/Saudi ArabiaAID55086.12014/Saudi ArabiaAID55085.12014/Saudi ArabiaAID55084.12014/Saudi ArabiaAID55083.12014/Saudi ArabiaAID55082.12014/Saudi ArabiaAID55081.12014/Saudi ArabiaAID55080.12014/Saudi ArabiaAID55079.12014/Saudi ArabiaALJ54478.129-Mar-2015Saudi ArabiaRespiratory secretionsALJ54477.129-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54473.105-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54472.101-May-2015/Saudi ArabiaRespiratory secretionsALJ54471.108-May-2015/Saudi ArabiaRespiratory secretionsALJ54470.110-May-2015/Saudi ArabiaRespiratory secretionsALJ54469.113-May-2015/Saudi ArabiaRespiratory secretionsALJ54468.110-May-2015/Saudi ArabiaRespiratory secretionsALJ54467.112-May-2015/Saudi ArabiaRespiratory secretionsALJ54466.112-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54465.107-Mar-2015/Saudi ArabiaRespiratory secretionsALJ54464.108-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54463.101-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54462.130-Jan-2015/Saudi ArabiaRespiratory secretionsALJ54461.110-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54460.121-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54459.121-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54458.123-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54457.123-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54456.126-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54454.128-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54455.128-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54453.106-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54452.114-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54451.114-Feb-2015/Saudi ArabiaRespiratory secretionsALJ54450.112-Feb-2015/Saudi ArabiaRespiratory secretions

In Silico PCR {#Sec4}
-------------

(<http://insilico.ehu.es/PCR_virus/>) In silico PCR amplification is a program that made amplification against sequenced viruses, by mimicking PCR amplification and primers confirmatory tools too; here it was used for the above viruses by using store gene bank sequence; it contains 1783 sequences from 1421 completely sequenced viruses (last update: 31 May 2010).

Determination of Conserved Regions {#Sec5}
----------------------------------

The retrieved sequences, which were collected from NCBI, were used as a platform to obtain the conserved regions by using multiple sequence alignment (MSA). Sequences were aligned with the aid of ClustalW as implemented in the BioEdit program, version 7.0.9.0.

B-Cell Epitope Prediction {#Sec6}
-------------------------

B-cell epitope is characterized by being hydrophilic, accessible, flexible, antigenic propensity and in a beta turn region. Thus, the classical propensity scale methods and hidden Markov model programmed software from IEDB analysis resource (<http://www.iedb.org/>) were used for the following aspects:

### Prediction of Linear B-Cell Epitopes {#Sec7}

BepiPred from immune epitope database and analysis resource (<http://toolsiedb.ofg/bcell/>) was used for linear B-cell epitope prediction from the conserved region with a default threshold value of 0.350. BepiPred combines the predictions of a hidden Markov model and the propensity scale of Parker et al. as it is described in Larsen et al. (Immunome Research, 2006).

### Prediction of Surface Accessibility {#Sec8}

By Emini surface accessibility prediction tool of the immune epitope database (IEDB), the surface-accessible epitopes were predicted from the conserved regions holding the default threshold value 1.000 or higher.

### Prediction of Epitope Antigenicity Sites {#Sec9}

The Kolaskar and Tongaonkar antigenicity method was used to determine the antigenic sites with a default threshold value of 1.045.

### Prediction of Epitope Hydrophilicity {#Sec10}

Parker hydrophilicity prediction tool was used to determine the hydrophilicity of the conserved regions; the threshold default value was 1.286.

### Prediction of Beta Turn Sites {#Sec11}

Chou and Fasman beta turn prediction method was used with the default threshold 1.009 to determine the sites that contain beta turns.

### Prediction of Flexibility {#Sec12}

Karplus and Schulz flexibility prediction tools were used for the prediction of chain flexibility in proteins (selection of peptide antigen) with default threshold value 0.992.

Thresholds of all tools were provided by IEDB and it is mainly calculated by the software as the average score of the tested protein for each corresponding tools.

T-Cell Epitope Prediction {#Sec13}
-------------------------

Scanning an antigen sequence for amino acid patterns indicative of:

### MHC Class I Binding Predictions {#Sec14}

Analysis of peptide binding to MHC class I molecules was assessed by the IEDB MHC I prediction tool <http://tools.iedb.org/mhci/n;> for MHC-I binding prediction, several alleles were used including HLA-A, HLA-B, HLA-C, and HLA-E that have been reported as frequent around the world. MHC-I peptide complex presentation to T lymphocytes undergo several steps. The attachment of cleaved peptides to MHC molecules step was predicted. Consensus method which combines ANN, SMM, and scoring matrices derived from combinatorial peptide libraries (Comblib_Sidney2008) was used. 9-mer epitope lengths were selected. All internationally conserved epitopes that bind to alleles at score equal or less than 1.0 percentile rank (low percentile rank = good binders) were selected for further analysis as in selecting thresholds (cutoffs) for MHC class I and II binding predictions, <http://help.iedb.org/entries/23854373-Selecting-thresholds-cut-offs-for-MHC-class-I-and-II-binding-predictions>.

Note: For S glycoprotein, the sequence was divided into ten parts due to software limitations, no more than 200 FASTA sequences interring \[[@CR7]--[@CR11]\].

### MHC Class II Binding Predictions {#Sec15}

Analysis of peptide binding to MHC class II molecules was assessed by the IEDB MHC II prediction tool <http://tools.immuneepitope.org/mhcii/>. For MHC-II binding prediction, the reference set of alleles was used, which include HLA-DQ, HLA-DP, and HLA-DR that are most frequent around the world. MHC class II groove has the ability to bind to peptides with different lengths. There are seven prediction methods in the IEDB MHC II prediction tool; NetMHCIIpan was used in this study; the conserved epitopes that bind to alleles at scores equal or less than 10 percentile rank were selected for further analysis as in selecting thresholds (cutoffs) for MHC class I and II binding predictions, <http://help.iedb.org/entries/23854373-Selecting-thresholds-cut-offs-for-MHC-class-I-and-II-binding-predictions> \[[@CR7], [@CR11]--[@CR14]\].

### Proteasomal Cleavage/TAP Transport/MHC Class I Combined Predictor {#Sec16}

This tool combines predictors of proteasomal processing, TAP transport, and MHC binding to produce an overall score for each peptide's intrinsic potential of being a T-cell epitope selected; in this study NetMHCpan was used with immunoproteasomal cleavage prediction; there are two types of proteasomes, the constitutively expressed "housekeeping" type and immunoproteasomes that are induced by IFN-γ secretion. Results can be displayed in proteasome score, TAP score, MHC score, processing score, total score, and IC50 score. Explanations of prediction output:

#### Proteasome cleavage {#Sec17}

The scores can be interpreted as logarithms of the total amount of cleavage site usage liberating the peptide C-terminus; it depends on a lot of other factors, e.g., the amount of source protein degraded.

#### TAP transport {#Sec18}

The TAP score estimates an effective −log (IC50) values for the binding to TAP of a peptide or its N-terminal prolonged precursors.

#### MHC binding {#Sec19}

The MHC binding prediction is identical to Class I with output −log (IC50) values.

#### Processing {#Sec20}

This score combines the proteasomal cleavage and TAP transport predictions. It predicts a quantity proportional to the amount of peptide present in the ER, where a peptide can bind to multiple MHC molecules. This allows predicting T-cell epitope candidates independent of MHC restriction.

#### Total {#Sec21}

This score combines the proteasomal cleavage, TAP transport, and MHC binding predictions. It predicts a quantity proportional to the amount of peptide presented by MHC molecules on the cell surface. High scores mean high efficiency.

### Neural Network-Based Prediction of Proteasomal Cleavage Sites (NetChop) and T-Cell Epitopes (NetCTL and NetCTLpan) {#Sec22}

NetChop that was used here is a predictor of proteasomal processing based upon a neural network. NetCTL and NetCTLpan are predictors of T-cell epitopes along a protein sequence. The positive predictions threshold, 0.5, 0.75, and 1, sequentially for all methods above are displayed in green, while the red color for prediction below the threshold.

### MHC-NP: Prediction of Peptides Naturally Processed by the MHC {#Sec23}

MHC-NP employs data obtained from MHC elution experiments in order to assess the probability that a given peptide is naturally processed and binds to a given MHC molecule. This tool used in this study was the winner of the second Machine Learning Competition in Immunology; it is composed of three groups of peptides, binders, nonbinders, and eluted peptides that considered as naturally processed peptides, so greater probe score considered naturally processing peptide.

Epitope Analysis Tools {#Sec24}
----------------------

### Population Coverage Calculation {#Sec25}

All potential MHC I and MHC II binders from spike glycoprotein, E protein, and S and E modified sequences were assessed for a population coverage against the whole world population especially Saudi Arabia with other reported MERS-CoV countries. Calculations are achieved using the selected MHC-I and MHC-II interacted alleles by the IEDB population coverage calculation tool <http://tools.iedb.org/tools/population/iedb_input;> it computes projected population coverage, average number of epitope hits/HLA combinations recognized by the population, and minimum number of epitope hits/HLA combinations recognized by 90% of the population (PC90).

Homology Modeling {#Sec26}
-----------------

The complete 3D structure of spike glycoprotein and envelope protein was obtained by phyre2 (<http://www.sbg.bio.ic.ac.uk/phyre2>) which uses advanced remote homology detection methods to build 3D models. UCSF Chimera (version 1.8) was used to visualize the 3D structure, which is currently available within the chimera package and available from the chimera website (<http://www.cgl.ucsf.edu/cimera>). Homology modeling was achieved for further verification of the service accessibility and hydrophilicity of B-lymphocyte epitopes predicted, as well as visualization of all predicted T-cell epitopes in the structural level.

In addition to the above methods, three other software were used to determine the effect that was induced in S and E reference sequences among the amino acid (SNP, single nucleotide polymorphism).

Confirmation of Amino Acid Change in Spike Glycoprotein (S) and Envelope Protein (E) Sequence {#Sec27}
---------------------------------------------------------------------------------------------

### PolyPhen-2 {#Sec28}

(Polymorphism Phenotyping v2) (<http://genetics.bwh.harvard.edu/pph2/index.shtml>) is an online bioinformatics program to automatically predict the consequence of an amino acid change on the structure and function of a protein was assessed here. Basically, this program searches for 3D protein structures, multiple alignments of homologous sequences, and amino acid contact information in several protein structure databases and then calculates position-specific independent count scores (PSIC) for each of two variants and then computes the PSIC score difference between two variants; PolyPhen scores were assigned as probably damaging (2.00 or more), possibly damaging (1.40--1.90), potentially damaging (1.0--1.50), and benign (0.00--0.90). Basically PolyPhen accepts input in form of SNPs or protein sequences \[[@CR18]\].

### I-Mutant Suite {#Sec29}

I used I-Mutant version 3.0 (<http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi>) to predict the protein stability changes upon single-site mutations. I-Mutant3.0 basically can evaluate the stability change of a single-site mutation starting from the protein structure or from the protein sequences. This program was trained on some data set derived from ProTherm which is considered to be the most comprehensive database of experimental data on protein mutations \[[@CR18]\].

### Project Hope Mutation {#Sec30}

(<http://www.cmbi.ru.nl/hope/>) Hope Version 1.1.0, HOPE is an easy-to-use web service that analyzes the structural effects of a point mutation in a protein sequence.

### SNPs and GO {#Sec31}

(<http://snps.biofold.org/snps-and-go//snps-and-go.html>) were used to predict disease-associated variations through using GO terms by collected information in a unique framework that derived from protein sequence, 3D structure, protein sequence profile, and protein function, beside gene ontology annotation to predict if a given variation can be classified disease-related or neutral. It calculates the result according to the three methods used depending on SVM type and data such as:

#### PANTHER {#Sec32}

output of the PANTHER algorithm.

#### PhD-SNP {#Sec33}

SVM input is the sequence and profile at the mutated position.

#### SNPs and GO {#Sec34}

SVM input is all the input in PhD-SNP, PANTHER, and GO term features, by giving disease probability (if \>0.5 mutation is predicted disease).

Peptide Search Tool {#Sec35}
-------------------

The peptide search tool was used to find all UniProtKB sequences that exactly match a query peptide sequence (<http://www.uniprot.org/peptidesearch/>). This means we can easily synthesis the desired peptides in the laboratory by cloning methods and so on to study peptide impact on immune system via injected laboratory animals with peptide sequence of any organisms.

AllerHunter {#Sec36}
-----------

(<http://tiger.dbs.nus.edu.sg/AllerHunter/index.html>) is a cross-reactive allergen prediction program built on a combination of support vector machine (SVM) and pairwise sequence similarity. Results of prediction of query sequence(s) can be achieved by using AllerHunter and FAO/WHO evaluation scheme; in AllerHunter sequence can be considered as a cross-reactive allergen if it has a probability of ≧0.06, while in the guideline of the FAO/WHO, they stated that a sequence is potentially allergenic if it either has an identity of at least 6 contiguous amino acids OR \>35 percent sequence identity over a window of 80 amino acids when compared to known allergens.

AlgPred: Prediction of Allergenic Proteins and Mapping of IgE Epitopes {#Sec37}
----------------------------------------------------------------------

(<http://www.imtech.res.in/raghava/algpred/index.html>) AlgPred used to predict allergenic protein and mapping of IgE epitopes by:It allows prediction of allergens based on similarity of known epitope with any region of protein.The mapping of IgE epitope(s) feature of server allows user to locate the position of epitope in their protein.Server search MEME/MAST allergen motifs using MAST and assign a protein allergen if it has any motif.It allows predicting allergens based on SVM modules using amino acid or dipeptide composition.It facilitates BLAST search against 2890 allergen-representative peptides (ARPs) obtained from Bjorklund et al. (2005) and assigns a protein allergen if it has a BLAST hit.Hybrid option of server allows predicting allergen using combined approach (SVMc + IgE epitope + ARPs BLAST + MAST).

VaxiJen v2.0 {#Sec38}
------------

(<http://www.ddg-pharmfac.net/vaxijen/VaxiJen/VaxiJen_help.html>) VaxiJen is the first server for alignment-independent prediction of protective antigens. It was developed to allow antigen classification solely based on the physicochemical properties of proteins without recourse to sequence alignment.

Results {#Sec39}
=======

Prediction of B-Cell Epitopes {#Sec40}
-----------------------------

Spike glycoprotein, E protein, and modified S and E protein were subjected to BepiPred linear epitope prediction, Emini surface accessibility, Kolaskar and Tongaonkar antigenicity, Parker hydrophobicity, Chou and Fasman beta turn prediction methods, and Karplus and Schulz flexibility in IEDB, as the results in Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}, [4](#Fig4){ref-type="fig"}, [5](#Fig5){ref-type="fig"}, [6](#Fig6){ref-type="fig"}, [7](#Fig7){ref-type="fig"}, [8](#Fig8){ref-type="fig"}, [9](#Fig9){ref-type="fig"}, [10](#Fig10){ref-type="fig"}, [11](#Fig11){ref-type="fig"}, [12](#Fig12){ref-type="fig"}, [13](#Fig13){ref-type="fig"}, [14](#Fig14){ref-type="fig"}, [15](#Fig15){ref-type="fig"}, [16](#Fig16){ref-type="fig"}, [17](#Fig17){ref-type="fig"}, [18](#Fig18){ref-type="fig"}, [19](#Fig19){ref-type="fig"}, [20](#Fig20){ref-type="fig"}, [21](#Fig21){ref-type="fig"}, [22](#Fig22){ref-type="fig"}, [23](#Fig23){ref-type="fig"}, and [24](#Fig24){ref-type="fig"}.Fig. 1BepiPred linear epitope prediction of S glycoprotein, the desired epitope residue showed in yellow color. The red horizontal line indicates surface accessibility threshold (0.35)Fig. 2Emini surface accessibility prediction of S glycoprotein. The desired epitope residue for surface accessibility showed in yellow color, while green color was below threshold (1.000)Fig. 3Kolaskar and Tongaonkar antigenicity prediction of S glycoprotein. The desired epitope residue for antigenicity showed in yellow color, while the green color below the red horizontal line indicates less antigenicity below (1.045)Fig. 4Parker hydrophilicity prediction of S glycoprotein. The desired epitope residue showed in yellow color. The red horizontal line indicates parker hydrophilicity threshold (1.286)Fig. 5Chou and Fasman beta turn prediction of S glycoprotein. The desired epitope residue showed in yellow color. The red horizontal line indicates beta turn prediction threshold (1.009)Fig. 6Karplus and Schulz flexibility prediction of S glycoprotein. The desired epitope residue showed in yellow color. The red horizontal line indicates surface accessibility threshold (0.35)Fig. 7BepiPred linear epitope prediction of S glycoprotein modified sequence. The desired epitope residue showed in yellow color. The red horizontal line indicates BepiPred Linear Epitope threshold (0.35)Fig. 8Emini surface accessibility prediction of S glycoprotein modified sequence. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicates surface accessibility threshold ≤ (1.000)Fig. 9Kolaskar and Tongaonkar antigenicity prediction of S glycoprotein modified sequence. The desired epitope residue showed in yellow color. The red horizontal line indicates antigenicity threshold ≤ (1.045)Fig. 10Parker hydrophilicity prediction of S glycoprotein modified sequence. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicates hydrophilicity threshold ≤ (1.286)Fig. 11Chou and Fasman beta turn prediction of S glycoprotein modified sequence. The desired epitope residue showed in yellow color. The red horizontal line indicates beta turn threshold (1.009)Fig. 12Karplus and Schulz flexibility prediction of S glycoprotein modified sequence. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicates flexibility threshold ≤ (0.992)Fig. 13BePipred linear epitope prediction of E protein. The desired epitope residue showed in yellow color. The red horizontal line indicates Bepipred Linear Epitope threshold ≤ (0.35)Fig. 14Emini surface accessibility prediction of E protein. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicates surface accessibility threshold (1.000)Fig. 15Kolaskar and Tongaonkar antigenicity prediction of E protein. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicates antigenicity threshold (1.045)Fig. 16Parker hydrophilicity prediction of E protein the desired epitope residue showed in yellow color. The red horizontal line indicates hydrophilicity threshold ≤ (1.286)Fig. 17Chou and Fasman beta turn prediction of E protein. The desired epitope residue showed in yellow color. The red horizontal line indicates beta turn threshold ≤ (1.009)Fig. 18Karplus and Schulz flexibility prediction of E protein. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicated flexibility below threshold (0.992)Fig. 19BepiPred linear epitope prediction of E protein modified sequence. The desired epitope residue showed in yellow color. The red horizontal line indicates BepiPred Linear Epitope threshold (0.35)Fig. 20Emini surface accessibility prediction of E protein modified sequence. The desired epitope residue showed in yellow color, above the red horizontal line threshold (1.000)Fig. 21Kolaskar and Tongaonkar Antigenicity prediction of E protein modified sequence. The desired epitope residue showed in yellow color, while green color indicates antigenicity below threshold (1.045)Fig. 22Parker hydrophilicity prediction of E protein modified sequence. The desired epitope residue showed in yellow color. The red horizontal line indicates hydrophilicity threshold ≤ (1.286)Fig. 23Chou and Fasman beta turn prediction of E protein modified sequence. The desired epitope residue showed in yellow color, while green color below the red horizontal line indicates low beta turn threshold ≤ (1.009)Fig. 24Karplus and Schulz flexibility prediction of E protein modified sequence. The desired epitope residue showed in yellow color that illustrates flexibility threshold ≤ (0.992)

### BepiPred Linear Epitope Prediction Method {#Sec41}

The average binder score of spike glycoprotein to B cell was 0.35; all values equal or greater than the default threshold 0.35 were predicted to be potential B-cell binders.

### Emini Surface Accessibility Prediction {#Sec42}

The average surface accessibility areas of the protein were scored as 1.000; all values equal or greater than the default threshold 1.0 were regarded potentially in the surface. A total number of positive S glycoprotein peptide represent 481 peptide out of 1349, while in E protein represents 23 out of 77 and in S and E modified sequence represents 485 out 485 and 17out of 77 peptides sequentially.

### Kolaskar and Tongaonkar Antigenicity {#Sec43}

The default threshold of antigenicity of the protein was 1.045; all values greater than 1.045 were considered as potential antigenic determinants. The positive result number of selected S glycoprotein peptide represents 655 out of 1348, while in E protein represents 55 out of 76 and in S and E modified sequence represents 668 out of 668 and 47 out of 76 peptides sequentially.

### Parker Hydrophilicity Prediction {#Sec44}

The average hydrophilicity score of the protein was 1.286; all values equal or greater than the default threshold 1.286 were potentially hydrophilic. The positive result number of S glycoprotein peptide represents 693 out of 1348, while in E protein represents 18 out of 76 and in S and E modified sequence represents 690 out of 695 and 20 out of 76 peptides sequentially.

### Chou and Fasman Beta Turn Prediction {#Sec45}

To determine the site that contains beta turns, the default threshold was 1.009; all values equal or greater than the default threshold were considered beta turn sites. The positive result number of selected peptide represents 668 out of 1348 in S glycoprotein, while it represents 19 out of 76 in E protein and 673 out of 673 with 21 out of 76 in both S and E modified sequence sequentially.

### Karplus and Schulz Flexibility Prediction {#Sec46}

The default threshold value 0.992 determined chain flexibility in proteins, so all values equal or greater than the default threshold were considered as chain flexibility of protein. The positive results of selected peptide represent 679 out of 1347 in S glycoprotein, and it represents 24 out of 24 in E protein beside represented 680 out of 681 and 24 out of 75 in S and E modified sequences sequentially.

The most common B-cell epitope for E protein is YVKFQDS in a position 69, while for E protein modified sequence, they are VYVPQQD, YVPQQDS, and PPLPED/PPLPEDV in positions 68, 69, and 77 respectively.

The most common B-cell epitopes for both S and modified S are DVGPDSV, PDSVKSA, DSVKSAC, PRPIDVS, HTPATDC, AKPSGSV, KPSGSVV, SGTPPQV, GTPPQVY, TPPQVYN, QLSPLEG, YGPLQTP, PRSVRSV, RSVRSVP, SVKSSQS, VKSSQSS, SQSSPII, and SLNTKYV in the following positions 23, 26, 27, 48, 211, 371, 372, 393, 394, 395, 547, 707, 750, 751, 855, 856, 859 (or 857 in modified S), and 1202 sequentially; but QVDQLNS and VDQLNSS in positions 772 and 773 are ordinary only found in S glycoprotein, while LTPTSSY, TPTSSYV, PTSSYVD, TSSYVDV, DHGDYYV, YSQDVKQ, ANQYSPC, NQYSPCV, and YYRKQLS in a positions 15, 16, 17, 18, 83, 108, 523, 524, and 543 sequentially are only found in S glycoprotein modified sequence.

T-Cell Epitope Prediction {#Sec47}
-------------------------

Spike glycoprotein, E protein, and S and E modified sequence were subjected to consensus method for MHC-I binding, NetMHCIIpan for MHC-II binding, NetMHCpan for proteasomal cleavage/ TAP transport/MHC class I combined predictor, NetChop and NetCTL for neural network-based prediction of proteasomal cleavage sites (NetChop), and T-cell epitopes (NetCTL and NetCTLpan) with MHC-NP for prediction of peptides that's naturally processed by the MHC in IEDB software program.

### MHC Class I Binding Predictions {#Sec48}

Analysis of peptide sequence that's binding to MHC class I molecules by consensus method was assessed by the conserved epitopes that bind to alleles at score equal or less than 1.0 percentile. The positive result numbers of selected peptide represent 602 out of 53,800 in S glycoprotein and 63 out of 3626 in E protein while in S and E modified sequence represents 612 out of 58,457 and 41 out of 3234 sequentially.

Seven alleles were not found in E protein modified sequence, including HLA-A∗03:01, HLA-A∗11:01, HLA-A∗31:01, HLA-A∗68:01, HLA-B∗14:02, HLA-B∗40:01, and HLA-B∗40:02, while in E protein four alleles were not found; they are HLA-B∗48:01, HLA-B∗58:02, HLA-C∗04:01, and HLA-E∗01:01; the ruminant of alleles are common between both of them; among them three peptide sequences are common such as CMTGFNTLL^n^, MTGFNTLLV^n^, and QCMTGFNTL^n^, while HLCVQCMTG, KPPLPEDVW, LLVCTAFLT, LLVQPALSL, LTATHLCVQ, LVCTAFLTA, PALSLYMTG, PNFFDFTVV^n^, SLYMTGRSV, VCTAFLTAT, VQERIGWFI, VQPALSLYM, VVCDITLLV, and WFIPNFFDF^n^ are only found in E modified sequence.

HLA-A∗02:01 allele showed higher frequency numbers six, followed by HLA-A∗23:01, HLA-A∗29:02, HLA-A∗68:02, and HLA-B∗46:01 that had four frequency numbers, and the same for the peptide sequences FIFTVVCAI, ITLLVCMAF, IVNFFIFTV^n^, and LVQPALYLY in E protein while in modified E, I found HLA-C∗03:03 represents higher frequency numbers forty-three, but HLA-A∗02:01, HLA-A∗02:06, HLA-A∗29:02, and HLA-B∗38:01 had the same frequency numbers three.

For the peptide sequences, I found FIFTVVCAI had a higher frequency numbers five, followed by ITLLVCMAF, IVNFFIFTV^n^, and LVQPALYLY in E protein; reverse E protein modified sequence, LVQPALSLY had a higher frequency numbers five then followed by CMTGFNTLL^n^, FLTATHLCV, FVQERIGWF, ITLLVCTAF, LYMTGRSVY, WFIPNFFDF^n^, and YMTGRSVYV which had a frequency numbers four except QCMTGFNTL^n^ that had three frequency numbers.

N.B: ^n^indicate presence of asparagine (N) in peptide sequences, that's hiding epitope from recognition by immune system so we should deal with the common epitope with the caution; they are 11 peptide sequence numbers with asparagine in E and 13 in modified E, while they are 8 in S and 46 in modified S sequence.

HLA-A∗30:02 allele was not found in S glycoprotein modified sequence, while HLA-B∗38:01, HLA-B∗39:01, HLA-B∗40:01, HLA-B∗40:02, HLA-B∗44:02, HLA-B∗44:03, HLA-B∗46:01, HLA-B∗48:01, HLA-B∗51:01, and HLA-B∗53:01 were not found in S sequence, but they were found in S modified sequence; these means 15 peptide sequences were absent in S sequence (AGYKVLPPL, APQVTYQNI^n^, CKLPLGQSL, CVFFILCCV, DVKQFDNGF^n^, DYYVYSAGH, FKLSIPTNF^n^, FLLTPTSSY, GEMRLASIA, GNYTYYHKW^n^, GPASARDLI, GTDTNSVCI^n^, HKWPWYIWL, HSKFLLMFL, IAPVNGYFI^n^) but presented in modified S sequence; besides this it also lakes a 34 peptide sequences like AGPISQFNY^n^, CMGKLKCNR^n^, DLSQLHCSY, DVKQFANGF^n^, FATYHTPAT, FLLTPTESY, FQFATLPVY, FVYDAYQNL^n^, GTNCMGKLK^n^, GVRQQRFVY, HSVFLLMFL, ICAQYVAGY, etc.; the other peptide sequences were not shown here.

In S glycoprotein HLA-A∗29:02 allele showed higher frequency numbers (41) then followed by HLA-A∗30:02 (37), HLA-A∗01:01 (31), HLA-B∗15:01 (29), HLA-C∗14:02 (27), HLA-A∗25:01 (25), HLA-A∗23:01 (24), HLA-B∗58:01 (23), and HLA-C∗06:02 (22); modified S glycoprotein sequence partially shared the same alleles with higher frequency numbers like in S glycoprotein which they are HLA-A∗29:02 allele that represented the most higher frequency numbers (33), followed by HLA-C∗14:02 (27), HLA-A∗01:01 (25), HLA-B∗46:01 (22)/HLA-A∗23:01, HLA-B∗58:01, and HLA-C∗06:02 (21)/HLA-B∗15:01 (20). In S glycoprotein the following peptide sequences had higher frequency numbers such as 10 in FSFGVTQEY and ITYQGLFPY peptides, 8 in WSYTGSSFY, 7 in KAWAAFYVY, and 6 in FVYDAYQNL^n^, and ITITYQGLF, QTAQGVHLF, while it represented 5 in FQFATLPVY, NSYTSFATY^n^, SLILDYFSY, STVWEDGDY, VSVPVSVIY, and YTYYNKWPW^n^, but in modified S glycoprotein, the frequencies were different, like 10 in FSFGVTQEY peptide, 4 in FLLTPTSSY, FSSRYVDLY, FVANYSQDV^n^, FYVYKLQPL, and IAFNHPIQV^n^, while it's 3 in ASIAFNHPI^n^, DEILEWFGI, DYFSYPLSM, EAAYTSSLL, FCSKINQAL^n^, FFNHTLVLL^n^, FQDELDEFF, FSDGKMGRF, FSNPTCLIL^n^, GEMRLASIA, GRFFNHTLV^n^, HISSTMSQY, and HKWPWYIWL peptides.

N.B: ^n^ indicate presence of asparagine (N) in peptide sequences, that's hiding epitope from recognition by immune system.

### MHC Class II Binding Predictions {#Sec49}

Analysis of peptide binding to MHC class II molecules was assessed by the conserved epitopes that bind to alleles at scores equal or less than 10 percentile rank; the positive result numbers of selected epitopes showed 212 out of 4819 epitopes in S glycoprotein, 685 out of 4148 in E protein, and 6896 out of 75,206 with 685 out of 4148 in both S and E modified proteins sequentially.

The following alleles are more common between S glycoprotein, E protein, and S and E modified sequences, and they are HLA-DPA1∗01:03/DPB1∗02:01, HLA-DPA1∗02:01/DPB1∗01:01, HLA-DRB1∗01:01, HLA-DRB1∗01:02, HLA-DRB1∗04:04, HLA-DRB1∗04:05, HLA-DRB1∗04:08, HLA-DRB1∗04:10, HLA-DRB1∗04:23, HLA-DRB1∗07:01, HLA-DRB1∗07:03, HLA-DRB1∗08:06, HLA-DRB1∗11:04, HLA-DRB1∗11:06, HLA-DRB1∗12:01, HLADRB1∗13:04, HLA-DRB1∗13:11, HLA-DRB1∗13:21, and HLA-DRB4∗01:01, but in S and modified S glycoprotein, both of them contain other 42 different alleles not shown here. In E and modified E protein, HLA-DRB1∗01:01 had higher frequency numbers of alleles which represented 20, followed by 17 in HLA-DRB1∗01:02, 11 in HLA-DRB1∗12:01, 10 in HLA-DRB1∗11:04, HLA-DRB1∗11:06, and HLA-DRB1∗13:11, and 9 in HLA-DRB1∗07:01, HLA-DRB1∗07:03 and HLA-DRB1∗13:21, while in S and modified S glycoprotein, those alleles below had higher frequency numbers, which represented (200/199) in HLA-DRB1∗04:08/(199/201) HLA-DRB1∗04:01, HLA-DRB1∗04:21, and HLA-DRB1∗04:26/(194/190) in HLA-DRB1∗09:01/(192/189) in HLA-DRB1∗04:05/(167/167) in HLA-DRB1∗07:01, HLA-DRB1∗07:03/(164/167) in HLA-DRB1∗15:02, (160/159) in HLA-DRB1∗13:02/(159/159) in HLA-DRB1∗11:14, HLA-DRB1∗11:20, and HLA-DRB1∗13:23, and (152/158) in HLA-DRB3∗01:01.

E and modified E protein had the same peptide sequences with same frequency numbers, but the higher frequency numbers only showed in peptides below; it represented 15 with GFNTLLVQPALSLYM^n^, 14 with TGFNTLLVQPALSLY^n^, 13 with FNTLLVQPALSLYMT, 12 with MTGFNTLLVQPALSL^n^, 11 with NTLLVQPALSLYMTG^n^, and 10 with ALSLYMTGRSVYVPQ, LSLYMTGRSVYVPQQ, PALSLYMTGRSVYVP, and QPALSLYMTGRSVYV peptides.

N.B:-The alleles below are not available for S glycoprotein, E protein, and S and E modified sequence, and they are DPA1∗01-DPB1∗ 04:01, DRB1∗03:09, DRB1∗08:17, and DRB1∗13:28.The same peptide sequence shared more than one allele gene or the same allele has a different peptide sequence.Variation in frequency numbers among both alleles and peptide sequences has been shown when comparing reference sequence of S & E protein with the modified sequence of both of them.^n^ that is present in peptide sequences above indicates presence of arginine in the sequence.

### Proteasomal Cleavage/TAP Transport/MHC Class I Combined Predictor {#Sec50}

In NetMHCpan high scores mean high efficiency due to prediction of a quantity proportional to the amount of peptide presented by MHC molecules on the cell surface; total score higher or equal to 0 were selected for S and modified S glycoprotein, while in E protein total score equal or higher than 0.3 was selected, but in modified E protein total score equal or higher than −2.82 was selected; *see* Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}.Table 3Illustrate the positive selected peptide sequences for both S and modified S glycoprotein sequence by NetMHCpan prediction toolSModified SAFYCILEPR^a^AFYCILEPR^a^ASLNSFKEY^a,b^ASLNSFKEY^a,b^ATDCSDGNY^a,b^ATDCSDGNY^a,b^AYQNLVGYY^a,b^AYQNLVGYY^a,b^ALALCVFFI^a^AAIPFAQSICGTLLRAFY^a^ALGAMQTGFCTFMYTYNI^a,b^AVNNNAQAL^b^CYSSLILDY^a^ALALCVFFI^a^CMGKLKCNR^a,b^CGTLLRAFY^a^DAYQNLVGY^a,b^CTFMYTYNI^a,b^ESFDVESGVCYSSLILDY^a^EMRLASIAF^a^CMGKLKCNR^a,b^ETKTHATLF^a^DLSQLHCSYESAALSAQL^a^DAYQNLVGY^a,b^FANGFVVRI ^b^ETKTHATLF^a^FLLTPTESY^a^EMRLASIAF^a^FFNHTLVLL^a,b^EAAYTSSLLFSDGKMGRF^a^ESAALSAQL^a^FSSRYVDLY^a^FLLTPTSSY^a^FQFATLPVYFFNHTLVLL^a,b^FSVDGYIRRFSDGKMGRF^a^FYVYKLQPL^a^FSSRYVDLY^a^FSNPTCLIL^a,b^FTNCNYNLT^b^FQNCTAVGV^a,b^FYVYKLQPL^a^FSFGVTQEY^a^FSNPTCLIL^a,b^FVVNAPNGL ^b^FQNCTAVGV^a,b^FQDELDEFF^a^FVYDAYQNL^b^GVHLFSSRY^a^FSFGVTQEY^a^GLVNSSLFV^a,b^FAQSIFYRLGYYSDDGNY^a,b^FQDELDEFF^a^GLYFMHVGY^a^GVHLFSSRY^a^GQGTHIVSFGVRQQRFVYGRLTTLNAF^a,b^GYYSDDGNY^a,b^HSVFLLMFLGLVNSSLFV^a,b^HISSTMSQY^a^GWTAGLSSFIEVDIQQTF^a^GRLTTLNAF^a,b^IIYPQGRTY^c^GLYFMHVGY^a^ITITYQGLFHISSTMSQY^a^ITYQGLFPY^a^IEVDIQQTF^a^ITEDEILEW^a^IIYPQTRTY^c^IASNCYSSL^a,b^ITYQGLFPY^a^ILATVPHNL^a,b^ITEDEILEW^a^ILDYFSYPL^a^IASNCYSSL^a,b^ITKPLKYSY^a^ILATVPHNL^a^IAFNHPIQV^a,b^ILDYFSYPL^a^IEVVSAYGL^a^ITKPLKYSY^a^IAGLVALAL^a^IAFNHPIQV^a,b^KQFANGFVV^a,b^ICAQYVAGYKAWAAFYVY^a^IPFAQSIFYKLQPLTFLL^c^IANKFNQAL ^b^KETKTHATL^a^IEVVSAYGL1KVTIADPGY^a^IPNFGSLTF ^b^KVTVDCKQY^a^IAGLVALAL^a^KELGNYTYY^a,b^KQFDNGFVV^a,b^KYVAPQVTY^a^KAWAAFYVY^a^LLRAFYCIL^a^KLQPLTFLW^c^LLDFSVDGYKETKTHATL^a^LPVYDTIKY^a^KVTVDCKQY^a^LYGGNMFQF^b^KVTIADPGY^a^LSGTPPQVY^a^KYVAPQVTY^a^LSLFSVNDF ^b^KELGNYTYY^a,b^LSIPTNFSF^a,b^LLRAFYCIL^a^LQMGFGITV^a^LPVYDTIKY^a^LINGRLTTL^a,b^LSGTPPQVY^a^LVRSESAAL^a^LTFLWDFSVLYFMHVGYY^a^LQMGFGITV^a^LVALALCVF^a^LSIPTNFSF^a,b^MGRFFNHTL^a,b^LGSIAGVGWMLGSSVGNF^a,b^LSSFAAIPFMGFGITVQY^a^LASELSNTF ^b^MTEQLQMGF^a^LINGRLTTL^a,b^MLKRRDSTYLVRSESAAL^a^MSQYSRSTR^a^LTFINTTLL^b^NLRNCTFMY^a,b^LYFMHVGYY^a^NSYTSFATY^a,b^LVALALCVF^a^NSVCPKLEF^a,b^MGRFFNHTL^a,b^NHIEVVSAY^a,b^MLGSSVGNF^a,b^NTTLLDLTY ^b^MGFGITVQY^a^PVYDTIKYYMSQYSRSTR^a^QFANGFVVR ^b^MTEQLQMGF^a^QTAQGVHLF^a^MEAAYTSSLQPLTFLLDF^c^NLRNCTFMY^a,b^QSFSNPTCL1^b^NSYTSFATY^a,b^QALHGANLR ^b^NSVCIKLEF^a,b^QSSPIIPGF^a^NHIEVVSAY^a,b^RFFNHTLVL^a,b^QTAQGVHLF^a^RNCTFMYTY^a^QLHCSYESFRLVFTNCNY^a,b^QPLTFLWDF^c^RSTRSMLKR^a^QSFSNPTCL^a,b^RSAIEDLLF^a^QQRFVYDAYSVFLLMFLLQVDQLNSSY ^b^SFKEYFNLR^a,b^QSSPIIPGF^a^SLNSFKEYF^a,b^RFFNHTLVL^a,b^SFDVESGVY^a^RNCTFMYTY^a,b^SGVYSVSSF^a^RLVFTNCNY^a,b^SLILDYFSY^a^RSTRSMLKR^a^SQFNYKQSF^a,b^RSAIEDLLF^a^SSAGPISQF^a^SFKEYFNLR^a,b^SPLEGGGWL^a^SLNSFKEYF^a,b^SQLGNCVEY^a,b^SFDVESGVY^a^STVAMTEQLSGVYSVSSF^a^STVWEDGDY^a^SLILDYFSY^a^SYINKCSRL^a,b^SPLEGGGWL^a^SSTMSQYSR^a^SQFNYKQSF^a,b^STLTPRSVR^a^SSAGPISQF^a^STRSMLKRR^a^STVWEDGDY^a^SVRNLFASV^a,b^SYINKCSRL^a,b^TFFDKTWPR^a^SSTMSQYSR^a^TYSNITITY^a,b^STRSMLKRR^a^TAVGVRQQR^a^SQLGNCVEY^a,b^TVWEDGDYY^a^STLTPRSVR^a^TLLDLTYEMSLLGSIAGVTSIPNFGSL^a,b^SVRNLFASV^a,b^TYQNISTNL^a,b^TFFDKTWPR^a^TYYNKWPWY^a,b^TYSNITITY^a,b^VSKADGIIY^a^TTITKPLKYVYKLQPLTF^a^TVWEDGDYY^a^VECDFSPLL^a^TAVGVRQQR^a^VYNFKRLVF^a,b^TTNEAFQKV^b^VASGSTVAMTSIPNFGSL^a,b^VSIVPSTVW^a^TYQNISTNL^a,b^VSVPVSVIY^a^TYYHKWPWY^a^VNAPNGLYF^a,b^VSKADGIIY^a^VVNAPNGLY^a,b^VECDFSPLL^a^VALALCVFF^a^VYKLQPLTF^a^VVKALNESY^a,b^VYNFKRLVF^a,b^WPWYIWLGF^a^VSIVPSTVW^a^WAAFYVYKL^a^VSVPVSVIY^a^YQGDHGDMY^c^VNAPNGLYF^a,b^YFNLRNCTF^a,b^VVNAPNGLY^a,b^YYSIIPHSI^a^VALALCVFF^a^YSIIPHSIR^a^VVKALNESY^a,b^YNLTKLLSL^a,b^WPWYIWLGF^a^YPLSMKSDL^a^WSYTGSSFYYSSLILDYF^a^WTAGLSSFAYGVSGRGVF^a^WAAFYVYKL^a^YINKCSRLL^a^YQGDHGDYY^c^YSLYGVSGR^a^YFNLRNCTF^a,b^YSYINKCSR^a,b^YNLTKLLSL^a,b^YYRKQLSPL^a^YSIIPHSIR^a^YSRSTRSML^a^YYSIIPHSI^a^YYSDDGNYY^a,b^YINKCSRLL^a,b^YYPSNHIEV^a,b^YPLSMKSDL^a^YAPEPITSL^a^YSSLILDYF^a^YTYYNKWPW^b,c^YSYINKCSR^a,b^YYNKWPWYI^b,c^YYRKQLSPL^a^YGVSGRGVF^a^YSLYGVSGR^a^YSRSTRSML^a^YYSDDGNYY^a,b^YAPEPITSL^a^YYPSNHIEV^a,b^YTYYHKWPW^c^YYHKWPWYI^ca^Indicates a common peptide sequence^b^Indicates presence of arginine in sequence^c^Indicates a partial similarity between both reference sequence and modified sequenceTable 4Illustrate the positive selected peptide sequences for both E and modified E protein by NetMHCpan prediction toolEModified EALYLYNTGR ^a^KPPLPEDVWCMAFLTATRFTVVCAITLFVQERIGLFITLLVCMAFLFIVNFFIF ^a^LVQPALYLYLYNTGRSVY ^a^MAFLTATRLRIGLFIVNF ^a^TLLVQPALY^a^Indicates presence of arginine in sequence

### Neural Network-Based Prediction of Proteasomal Cleavage Sites (NetChop) and T-Cell Epitopes (NetCTL and NetCTLpan) {#Sec51}

The positive prediction thresholds are 0.5 and 0.75 (green color) for NetChop and NetCTL sequentially considered as proteasomal cleavage sites for T-cell epitopes; *see* Figs. [25](#Fig25){ref-type="fig"}, [26](#Fig26){ref-type="fig"}, [27](#Fig27){ref-type="fig"}, [28](#Fig28){ref-type="fig"}, [29](#Fig29){ref-type="fig"}, [30](#Fig30){ref-type="fig"}, [31](#Fig31){ref-type="fig"}, [32](#Fig32){ref-type="fig"}, [33](#Fig33){ref-type="fig"}, [34](#Fig34){ref-type="fig"}, [35](#Fig35){ref-type="fig"}, [36](#Fig36){ref-type="fig"}, [37](#Fig37){ref-type="fig"}, and [38](#Fig38){ref-type="fig"} with Table [5](#Tab5){ref-type="table"}.Fig. 25Illustrate the NetChop positive prediction of E protein with threshold equal or greater than 0.5Fig. 26Illustrate the NetChop positive prediction of modified E protein threshold equal or greater than 0.5Fig. 27Illustrate the NetCTL positive prediction of E protein supertype A1 that's indicated in a green color with threshold equal or greater than 0.75 above the red colorFig. 28Illustrate the NetCTL prediction of E protein supertype A2, the desired supertype A2 appeared in a green color with threshold equal or greater than 0.75 above the threshold red colorFig. 29Illustrate the NetCTL prediction of E protein supertype A3, the positive results appeared in a green color with threshold equal or greater than 0.75 above the red colorFig. 30Illustrate the NetCTL prediction of E protein supertype A24, positive results appeared in a green color with threshold equal or greater than 0.75 above the threshold red colorFig. 31Illustrate the NetCTL prediction of E protein supertype A26, positive results appeared in a green color with threshold equal or greater than 0.75 above the threshold red colorFig. 32Illustrate the NetCTL negative prediction of E protein supertype B7 with threshold below 0.75Fig. 33Illustrate the NetCTL negative prediction of E protein supertype B8 with threshold below 0.75Fig. 34Illustrate the NetCTL negative prediction of E protein supertype B27Fig. 35Illustrate the NetCTL negative prediction of E protein supertype B39 with threshold below 0.75Fig. 36Illustrate the NetCTL negative prediction of E protein supertype B44 with threshold below 0.75Fig. 37Illustrate the NetCTL prediction of E protein supertype B58, positive results appeared in a green colored with threshold equal or greater than 0.75 above the threshold red colorFig. 38Illustrate the NetCTL prediction of E protein supertype B62, positive results appeared in a green colored with threshold equal or greater than 0.75 above the threshold red colorTable 5Illustrate NetCTL +ve results in E and modified E protein with indications of similarities and differences in the peptide sequences between them, beside the totals numbers of themSupertypePeptide sequence for E proteinPeptide sequence for modified E proteinResidue position for E/modified E proteinA1LVQPALYLYLVQPALSLY51/51LYNTGRSVY58/58A2FVQERIGWFFVQERIGWF4/4VVCDITLLVVVCDITLLV21/21FLTATHLCVFLTATHLCV33/33LLVQPALSLLLVQPALSL50/50SLYMTGRSVSLYMTGRSV57/57YMTGRSVYVYMTGRSVYV59/59A3ALYLYNTGRALSLYMTGR55/55NTGRSVYVK60/−VYVKFQDSK65/−A24MLPFVQERIMLQFVQERI1/1PFVQERIGLFVQERIGWF3/4FVQERIGLFRIGWFIPNF4/8RIGLFIVNFWFIPNFFDF8/11IGLFIVNFFFTVVCDITL9/19LFIVNFFIFITLLVCTAF11/25FTVVCAITLLVQPALSLY19/51ITLLVCMAFLYMTGRSVY25/58MAFLTATRL31/−LVQPALYLY51/−LYNTGRSVY58/−TGRSVYVKF61/−KFQDSKPPL68/−A26FVQERIGWFFVQERIGWF4/4RIGWFIPNFRIGWFIPNF8/8WFIPNFFDFWFIPNFFDF11/11TVVCDITLLTVVCDITLL20/20ITLLVCTAFITLLVCTAF25/25ATHLCVQCMATHLCVQCM36/36LCVQCMTGFLCVQCMTGF39/39QCMTGFNTLQCMTGFNTL42/42NTLLVQPALNTLLVQPAL48/48LVQPALSLYLVQPALSLY51/51B7--LLVQPALSL−/50QPALSLYMT−/53KPPLPEDVW−/3B8FVQERIGLFFVQERIGWF4/4TGRSVYVKFWFIPNFFDF61/11B27------B39YNTGRSVYVYMTGRSVYV59/59KFQDSKPPL68B44------B58ITLLVCMAFIGWFIPNFF25/9KPPLPPDEWITLLVCTAF73/25KPPLPEDVW−/3B62FVQERIGLFFVQERIGWF4/4ITLLVCMAFWFIPNFFDF25/11TLLVQPALYITLLVCTAF49/25LVQPALYLYLVQPALSLY51/51YLYNTGRSVLYMTGRSVY57/58

NetChop prediction score equal or greater than 0.5 in S glycoprotein represented a positive result; more than 300 peptides out of 1353 showed positive results, while in modified S glycoprotein, 5 out of 66 showed positive results, in E protein 28 out of 82 were positive, and 28 out of 82 in modified E protein were positive.

Both E & modified E protein showed 28 amino acid that's crossed the threshold; 0.5 with same residue position like: F → 33; L → 58, 50, 39, 51, 28, 56, 2; Q → 70; R → 63; Y → 59 and 66; V → 67, 65, 41, 21, 22, 52, 29; except: V → 82 in E protein while it's at position 10 in modified E protein, L → 76 in E protein while at position 34 and 6 in modified E protein, F → 69 in E protein while it's at positions 17 and 19 in modified E protein, W → 81 in E while it's at position 11 in modified E protein, R → 38 in E, I → 18 in E, K → 68 and 73 in E while A → 32 in modified E protein with M → 60,Y → 57 in E protein.

N.B:-.Peptide sequences of both E and modified E protein were different even if they had a similar residue position.NetCTL was used for E and modified E protein just due to large amounts of data beside, time-consuming when it is used with S glycoprotein.Modified E protein NetCTL charts were not shown here.

### MHC-NP: Prediction of Peptides Naturally Processed by the MHC {#Sec52}

The greater probe score was considered as naturally processing peptide; probe scores greater than 0 were considered as naturally processing peptides.

The total positive epitope number of naturally processing peptides represented 10,189 out of 10,760 in S glycoprotein and 10,187 out of 10,760 in modified S glycoprotein, while it represents 568 out of 592 in E and 566 out of 592 in modified E protein.

E protein showed alleles frequencies: H-2-Db (74), H-2-Kb (74), HLA-A∗02:01 (68), HLA-B∗07:02 (66), HLA-B∗35:01 (74), HLA-B∗44:03 (74), HLA-B∗53:01 (73), HLA-B∗57:01 (62) while in modified E they are H-2-Db (28), H-2-Kb (16), HLA-A∗02:01 (5), HLA-B∗07:02 (2), HLA-B∗35:01 (6), HLA-B∗44:03 (28), HLA-B∗53:01 (60), and HLA-B∗57:01 (4).

N.B: modified E protein showed less allele frequency when compared with E protein in addition to some epitope differences even if at the same positions.

Epitope Analysis Tools {#Sec53}
----------------------

### Population Coverage Calculation {#Sec54}

MHC-I and MHC-II interacted alleles by the IEDB population coverage calculation tool was computed by the average number of epitope hits/HLA combinations recognized by the population and a minimum number of epitope hits/HLA combinations recognized by 90% of the population (PC90); see tables below.

Those below represented a selected E protein epitopes for population coverage calculation:

PFVQER, VQERIG, QERIGL, FLTATR, LYLYNT, YLYNTG, LYNTGR, YNTGRS, NTGRSV, TGRSVY, RSVYVK, YVKFQD, VKFQDS, KFQDSK, FQDSKP, QDSKPP, DSKPPL, SKPPLP, KPPLPP, PPLPPD, PLPPDE, LPPDEW, PPDEWV, MLPFVQE, LPFVQER, PFVQERI, VQERIGL, RIGLFIV, IGLFIVN, GLFIVNF, LFIVNFF, FIVNFFI, IVNFFIF, and VNFFIFT.

There are differences between MHC-I and MHC-II population coverage percentage.

There are similarities between MHC-I between both E and modified E protein, but still there are differences between them at MHC-II.

Those below represented a selected modified E protein epitopes for population coverage calculation:

RSVYVP, LYMTGR, VYVPQQ, PLPEDV, QERIGW, TGRSVY, YMTGRS, QFVQER, VPQQDS, SKPPLP, PPLPED, DSKPPL, YVPQQD, KPPLPE, QDSKPP, PQQDSK, QQDSKP, PLPEDVW, QFVQERI, AFLTATH, MLQFVQE, ALSLYMT, LQFVQER, VQCMTGF, YVPQQDS, GFNTLLV, PPLPEDV, FLTATHL, TGRSVYV, PALSLYM, NTLLVQP, FNTLLVQ, LPEDVWV, and CTAFLTA.

The percentage of a coverage population was similar among both S glycoprotein reference sequence and modified S glycoprotein; it represented 95.60% of the world by MHC-I; 118 countries showed a higher percentage especially Chile Amerindian (100%), 69 other countries showed 0% while in East Asia (94.80%), South Korea and South Oriental Korea (92.84%), China (88.77%), Iran and Iran Persian (91.53%) but Iran Kurd (0.00%), Jordan and Jordan Arab (76.80%),Oman and Oman Arab (95.82%), Saudi Arabia and Saudi Arabia Arab (96.38%), United Arab Emirates and United Arab Emirates Arab (0.00%), Sudan (86.43%), Sudan Arab (49.41%), Sudan Black (0.00%), and Sudan Mixed (87.06%); please *see* Table [6](#Tab6){ref-type="table"}.Table 6MHC-I coverage population for S and modified S glycoproteinPopulation/AreaClass ICoverage^a^Average hit^b^PC90^c^World95.60%10.574.38East Asia94.80%10.932.58Japan96.19%11.443.12Japan Oriental96.19%11.443.12Korea, South92.84%10.412.16Korea, South Oriental92.84%10.412.16Mongolia94.37%10.073.12Mongolia Oriental94.37%10.073.12Northeast Asia88.80%9.380.89China88.77%9.330.89China Oriental88.77%9.330.89Hong Kong90.85%10.011.91Hong Kong Oriental90.85%10.011.91South Asia86.54%8.030.74India82.00%7.210.56India Asian82.00%7.210.56Pakistan88.63%8.741.76Pakistan Asian87.30%8.381.58Pakistan Mixed91.12%9.423.23Sri Lanka52.39%3.740.84Sri Lanka Asian52.39%3.740.84Southeast Asia87.81%9.990.82Borneo0.00%0?Borneo Austronesian0.00%0?Indonesia76.44%7.80.42Indonesia Austronesian76.44%7.80.42Malaysia76.30%7.640.42Malaysia Austronesian40.59%3.170.34Malaysia Oriental84.44%9.020.64Philippines92.86%11.568.01Philippines Austronesian92.86%11.568.01Singapore85.74%9.040.7Singapore Austronesian82.82%8.550.58Singapore Oriental88.96%9.640.91Taiwan92.58%11.316.08Taiwan Oriental92.58%11.316.08Thailand82.85%7.460.58Thailand Oriental82.85%7.460.58Vietnam84.58%8.550.65Vietnam Oriental84.58%8.550.65Southwest Asia85.77%7.590.7Iran91.53%8.61.33Iran Kurd0.00%0?Iran Persian91.53%8.61.33Israel82.14%7.290.56Israel Arab89.15%9.130.92Israel Jew87.17%7.840.78Jordan76.80%6.520.43Jordan Arab76.80%6.520.43Lebanon0.00%00Lebanon Arab0.00%0?Lebanon Mixed0.00%00Oman95.82%9.963.04Oman Arab95.82%9.963.04Saudi Arabia96.38%9.873.65Saudi Arabia Arab96.38%9.873.65United Arab Emirates0.00%00United Arab Emirates Arab0.00%00Europe97.81%11.075.29Austria98.78%11.296Austria Caucasoid98.78%11.296Belarus0.00%0?Belarus Caucasoid0.00%0?Belgium98.75%10.626.02Belgium Caucasoid98.75%10.626.02Bulgaria96.59%11.084.52Bulgaria Caucasoid96.56%11.254.57Bulgaria Other97.43%10.024.35Croatia97.76%11.796.12Croatia Caucasoid97.76%11.796.12Czech Republic96.20%9.394.33Czech Republic Caucasoid96.20%9.394.33Czech Republic Other0.00%0?Denmark0.00%00Denmark Caucasoid0.00%00England99.29%11.436.21England Caucasoid99.29%11.436.21England Jew0.00%00England Mixed0.00%0?Finland99.80%12.567.8Finland Caucasoid99.80%12.567.8France98.05%10.724.75France Caucasoid98.05%10.724.75Georgia95.62%10.984.48Georgia Caucasoid97.22%11.666.21Georgia Kurd89.99%9.261Germany99.07%11.716.4Germany Caucasoid99.07%11.716.4Greece0.00%0?Greece Caucasoid0.00%0?Ireland Northern99.40%11.436.27Ireland Northern Caucasoid99.40%11.436.27Ireland South98.83%10.824.85Ireland South Caucasoid98.83%10.824.85Italy96.52%9.834.16Italy Caucasoid96.52%9.834.16Macedonia11.83%0.860.45Macedonia Caucasoid11.83%0.860.45Netherlands0.00%0?Netherlands Caucasoid0.00%0?Norway0.00%0?Norway Caucasoid0.00%0?Poland97.99%11.256.02Poland Caucasoid97.99%11.256.02Portugal97.11%10.984.73Portugal Caucasoid97.11%10.984.73Romania97.94%11.565.94Romania Caucasoid97.94%11.565.94Russia96.71%11.384.59Russia Caucasoid0.00%00Russia Mixed0.00%00Russia Other98.34%12.466.71Russia Siberian97.30%11.524.53Scotland15.91%0.810.24Scotland Caucasoid15.91%0.810.24Serbia43.75%0.780.18Serbia Caucasoid43.75%0.780.18Slovakia0.00%0?Slovakia Caucasoid0.00%0?Slovenia0.00%0?Slovenia Caucasoid0.00%0?Spain71.85%5.510.36Spain Caucasoid71.85%5.510.36Spain Jew0.00%0?Spain Other0.00%0?Sweden99.69%12.616.84Sweden Caucasoid99.69%12.616.84Switzerland0.00%00Switzerland Caucasoid0.00%00Turkey44.80%3.581.45Turkey Caucasoid44.80%3.581.45Ukraine0.00%0?Ukraine Caucasoid0.00%0?United Kingdom0.00%00United Kingdom Caucasoid0.00%00Wales0.00%00Wales Caucasoid0.00%00East Africa86.99%6.960.77Kenya85.86%6.620.71Kenya Black85.86%6.620.71Uganda91.04%8.191.48Uganda Black91.04%8.191.48Zambia95.32%7.984.01Zambia Black95.32%7.984.01Zimbabwe91.57%7.691.71Zimbabwe Black91.57%7.691.71West Africa92.60%8.711.67Burkina Faso58.50%3.240.24Burkina Faso Black58.50%3.240.24Cape Verde96.69%10.094.14Cape Verde Black96.69%10.094.14Gambia0.00%0?Gambia Black0.00%0?Ghana0.00%00Ghana Black0.00%00Guinea-Bissau92.66%8.71.49Guinea-Bissau Black92.66%8.71.49Ivory Coast58.05%0.780.24Ivory Coast Black58.05%0.780.24Liberia0.00%0?Liberia Black0.00%0?Nigeria0.00%0?Nigeria Black0.00%0?Senegal95.03%9.114Senegal Black95.03%9.114Central Africa84.98%6.70.67Cameroon88.67%7.350.88Cameroon Black88.67%7.350.88Central African Republic10.75%0.270.11Central African Republic Black10.75%0.270.11Congo0.00%0?Congo Black0.00%0?Equatorial Guinea0.00%00Equatorial Guinea Black0.00%00Gabon0.00%0?Gabon Black0.00%0?Rwanda23.09%1.330.13Rwanda Black23.09%1.330.13Sao Tome and Principe95.54%8.722.29Sao Tome and Principe Black95.54%8.722.29North Africa91.87%8.611.86Algeria0.00%0?Algeria Arab0.00%0?Ethiopia0.00%0?Ethiopia Black0.00%0?Mali94.28%8.821.74Mali Black94.28%8.821.74Morocco95.95%9.474.19Morocco Arab97.89%10.24.47Morocco Caucasoid94.32%8.964.02Sudan86.43%7.530.74Sudan Arab49.41%4.620.59Sudan Black0.00%00Sudan Mixed87.06%7.560.77Tunisia96.04%9.854.19Tunisia Arab96.04%9.854.19Tunisia Berber0.00%0?South Africa91.05%82.1South Africa91.05%82.1South Africa Black86.71%6.670.75South Africa Other93.82%9.592.73West Indies97.34%10.784.6Cuba97.20%10.654.53Cuba Caucasoid97.64%11.24.77Cuba Mixed0.00%0?Cuba Mulatto96.58%9.664.09Jamaica0.00%0?Jamaica Black0.00%0?Martinique22.56%2.031.16Martinique Black22.56%2.031.16Trinidad and Tobago0.00%00Trinidad and Tobago Asian0.00%00North America96.88%10.984.65Canada0.00%0?Canada Amerindian0.00%0?Mexico97.10%116.02Mexico Amerindian99.86%137.84Mexico Mestizo96.78%10.74.46United States96.93%10.984.66United States Amerindian99.44%13.158.19United States Asian92.39%10.322.29United States Austronesian0.00%0?United States Black94.18%8.832.54United States Caucasoid98.65%11.46.08United States Hispanic97.46%11.014.77United States Mestizo98.09%11.24.97United States Polynesian97.53%11.573.62Central America5.10%0.160.11Costa Rica0.00%0?Costa Rica Mestizo0.00%0?Guatemala5.10%0.160.11Guatemala Amerindian5.10%0.160.11South America86.24%8.010.73Argentina98.02%8.762.61Argentina Amerindian98.02%8.762.61Argentina Caucasoid0.00%0?Bolivia0.00%0?Bolivia Amerindian0.00%0?Brazil93.72%9.432.69Brazil Amerindian92.35%8.372.16Brazil Caucasoid97.68%11.335.35Brazil Mixed95.06%9.853.75Brazil Mulatto0.00%0?Brazil Other0.00%00Chile94.93%10.634.37Chile Amerindian100.00%14.319.11Chile Hispanic0.00%0?Chile Mixed87.43%8.160.8Colombia9.86%0.760.67Colombia Amerindian0.00%00Colombia Black5.79%0.420.64Colombia Mestizo14.81%1.170.7Ecuador76.97%8.771.74Ecuador Amerindian76.97%8.771.74Ecuador Black0.00%0?Paraguay0.00%0?Paraguay Amerindian0.00%0?Peru99.98%13.698.37Peru Amerindian99.98%13.698.37Peru Mestizo0.00%00Venezuela88.37%9.050.86Venezuela Amerindian88.88%8.980.9Venezuela Caucasoid9.18%0.830.99Venezuela Mestizo7.84%0.710.98Venezuela Mixed0.00%0?Oceania91.82%10.924.06American Samoa95.26%12.147.15American Samoa Polynesian95.26%12.147.15Australia89.30%9.930.93Australia Australian Aborigines82.36%9.310.57Australia Caucasoid99.06%11.466.16Chile94.93%10.634.37Chile Amerindian100.00%14.319.11Cook Islands0.00%0?Cook Islands Polynesian0.00%0?Fiji0.00%0?Fiji Melanesian0.00%0?Kiribati0.00%0?Kiribati Micronesian0.00%0?Nauru0.00%0?Nauru Micronesian0.00%0?New Caledonia96.70%12.148.63New Caledonia Melanesian96.70%12.148.63New Zealand0.00%0?New Zealand Polynesian0.00%0?Niue0.00%0?Niue Polynesian0.00%0?Papua New Guinea97.26%12.588.57Papua New Guinea Melanesian97.26%12.588.57Samoa0.00%0?Samoa Polynesian0.00%0?Tokelau0.00%0?Tokelau Polynesian0.00%0?Tonga0.00%0?Tonga Polynesian0.00%0?Average55.31%5.73?(Standard deviation)−44.16%−4.92(?)^a^Projected population coverage^b^Average number of epitope hits/HLA combinations recognized by the population^c^Minimum number of epitope hits/HLA combinations recognized by 90% of the population

According to the percentage of a coverage population that was similar between S glycoprotein reference sequence and modified S glycoprotein, the world MHC-II represent 81.81%; 64 countries showed a higher percentage especially Norway and Norway Caucasoid (94.71%), 59 other countries (0%) while in East Asia represents (94.80%), South Korea and South Oriental Korea (85.32%), China (59.99%), Iran (64.22%), Iran Persian (55.78%), Iran Kurd (65.72%), Jordan and Jordan Arab (52.88%), Oman and Oman Arab (0.00%), Saudi Arabia and Saudi Arabia Arab (80.14%), United Arab Emirates and United Arab Emirates Arab (32.92%), Sudan (60.56%), Sudan Arab (0.00%), Sudan Black (0.00%), and Sudan Mixed (60.56%), as in Table [7](#Tab7){ref-type="table"}.Table 7The MHC-II coverage population for S and modified S glycoproteinPopulation/AreaClass IICoverage^a^Average hit^b^PC90^c^World81.81%8.161.1East Asia81.82%8.831.1Japan74.83%7.850.79Japan Oriental74.83%7.850.79Korea, South85.32%9.561.36Korea, South Oriental85.32%9.561.36Mongolia81.85%7.791.1Mongolia Oriental81.85%7.791.1Northeast Asia59.99%5.330.5China59.99%5.330.5China Oriental59.99%5.330.5Hong Kong0.00%0?Hong Kong Oriental0.00%0?South Asia75.38%7.40.81India74.99%7.350.8India Asian74.99%7.350.8Pakistan1.18%0.090.81Pakistan Asian1.45%0.120.81Pakistan Mixed0.00%00Sri Lanka0.00%0?Sri Lanka Asian0.00%0?Southeast Asia56.98%4.980.46Borneo49.02%4.030.39Borneo Austronesian49.02%4.030.39Indonesia47.84%4.40.38Indonesia Austronesian47.84%4.40.38Malaysia57.99%5.340.48Malaysia Austronesian55.38%5.120.45Malaysia Oriental70.35%6.570.67Philippines28.56%2.520.28Philippines Austronesian28.56%2.520.28Singapore65.78%6.040.58Singapore Austronesian65.78%6.040.58Singapore Oriental0.00%0?Taiwan67.88%6.130.62Taiwan Oriental67.88%6.130.62Thailand63.90%5.920.55Thailand Oriental63.90%5.920.55Vietnam54.44%4.430.44Vietnam Oriental54.44%4.430.44Southwest Asia43.93%3.650.36Iran64.22%5.650.56Iran Kurd55.78%4.740.45Iran Persian65.72%5.830.58Israel68.79%6.40.64Israel Arab67.51%6.20.62Israel Jew69.65%6.510.66Jordan52.88%4.560.42Jordan Arab52.88%4.560.42Lebanon70.46%6.480.68Lebanon Arab70.46%6.480.68Lebanon Mixed0.00%0?Oman0.00%0?Oman Arab0.00%0?Saudi Arabia80.14%8.311.01Saudi Arabia Arab80.14%8.311.01United Arab Emirates32.92%0.660.3United Arab Emirates Arab32.92%0.660.3Europe85.83%8.881.41Austria93.34%10.82.82Austria Caucasoid93.34%10.82.82Belarus43.81%3.551.25Belarus Caucasoid43.81%3.551.25Belgium79.39%7.160.97Belgium Caucasoid79.39%7.160.97Bulgaria57.23%4.950.47Bulgaria Caucasoid57.23%4.950.47Bulgaria Other0.00%0?Croatia66.71%5.890.6Croatia Caucasoid66.71%5.890.6Czech Republic86.21%9.231.45Czech Republic Caucasoid88.76%9.661.78Czech Republic Other64.14%6.40.56Denmark88.98%9.041.81Denmark Caucasoid88.98%9.041.81England93.48%10.492.74England Caucasoid93.48%10.492.74England Jew0.00%0?England Mixed0.00%00Finland51.14%4.240.41Finland Caucasoid51.14%4.240.41France88.54%9.291.74France Caucasoid88.54%9.291.74Georgia75.05%7.090.8Georgia Caucasoid75.05%7.090.8Georgia Kurd0.00%0?Germany91.14%10.142.26Germany Caucasoid91.14%10.142.26Greece66.92%6.290.6Greece Caucasoid66.92%6.290.6Ireland Northern94.65%10.582.89Ireland Northern Caucasoid94.65%10.582.89Ireland South93.15%102.51Ireland South Caucasoid93.15%102.51Italy85.90%5.931.42Italy Caucasoid85.90%5.931.42Macedonia66.53%6.20.6Macedonia Caucasoid66.53%6.20.6Netherlands83.44%8.331.21Netherlands Caucasoid83.44%8.331.21Norway94.71%10.563.01Norway Caucasoid94.71%10.563.01Poland84.46%8.851.29Poland Caucasoid84.46%8.851.29Portugal78.00%7.740.91Portugal Caucasoid78.00%7.740.91Romania0.00%0?Romania Caucasoid0.00%0?Russia77.62%7.240.89Russia Caucasoid88.52%9.811.74Russia Mixed0.00%00Russia Other85.01%9.21.33Russia Siberian78.83%7.140.94Scotland90.82%10.12.2Scotland Caucasoid90.82%10.12.2Serbia0.00%0?Serbia Caucasoid0.00%0?Slovakia18.28%0.370.24Slovakia Caucasoid18.28%0.370.24Slovenia84.85%8.741.32Slovenia Caucasoid84.85%8.741.32Spain80.51%8.281.03Spain Caucasoid80.84%8.341.04Spain Jew0.00%0?Spain Other6.30%0.570.96Sweden88.07%9.131.68Sweden Caucasoid88.07%9.131.68Switzerland0.00%0?Switzerland Caucasoid0.00%0?Turkey76.19%7.30.84Turkey Caucasoid76.19%7.30.84Ukraine50.64%4.171.42Ukraine Caucasoid50.64%4.171.42United Kingdom0.00%00United Kingdom Caucasoid0.00%00Wales0.00%00Wales Caucasoid0.00%00East Africa68.30%5.650.63Kenya0.00%00Kenya Black0.00%00Uganda0.00%00Uganda Black0.00%00Zambia0.00%0?Zambia Black0.00%0?Zimbabwe68.30%5.650.63Zimbabwe Black68.30%5.650.63West Africa65.23%6.130.58Burkina Faso0.00%0?Burkina Faso Black0.00%0?Cape Verde80.38%8.11.02Cape Verde Black80.38%8.11.02Gambia0.00%00Gambia Black0.00%00Ghana0.00%0?Ghana Black0.00%0?Guinea-Bissau71.16%7.040.69Guinea-Bissau Black71.16%7.040.69Ivory Coast0.00%0?Ivory Coast Black0.00%0?Liberia0.00%00Liberia Black0.00%00Nigeria0.00%00Nigeria Black0.00%00Senegal30.28%2.320.29Senegal Black30.28%2.320.29Central Africa62.71%5.170.54Cameroon49.87%3.310.4Cameroon Black49.87%3.310.4Central African Republic82.69%6.471.16Central African Republic Black82.69%6.471.16Congo68.66%5.930.64Congo Black68.66%5.930.64Equatorial Guinea47.58%3.550.38Equatorial Guinea Black47.58%3.550.38Gabon41.78%3.841.2Gabon Black41.78%3.841.2Rwanda62.79%5.380.54Rwanda Black62.79%5.380.54Sao Tome and Principe66.50%4.890.6Sao Tome and Principe Black66.50%4.890.6North Africa75.06%70.8Algeria77.15%7.250.88Algeria Arab77.15%7.250.88Ethiopia83.00%8.711.18Ethiopia Black83.00%8.711.18Mali0.00%0?Mali Black0.00%0?Morocco83.44%8.141.21Morocco Arab85.07%8.251.34Morocco Caucasoid79.75%8.070.99Sudan60.56%4.520.51Sudan Arab0.00%0?Sudan Black0.00%00Sudan Mixed60.56%4.520.51Tunisia74.26%6.820.78Tunisia Arab74.97%6.780.8Tunisia Berber74.47%7.430.78South Africa32.10%1.110.29South Africa32.10%1.110.29South Africa Black32.10%1.110.29South Africa Other0.00%0?West Indies69.22%6.670.65Cuba85.48%9.661.38Cuba Caucasoid0.00%0?Cuba Mixed85.48%9.661.38Cuba Mulatto0.00%0?Jamaica27.41%2.280.28Jamaica Black27.41%2.280.28Martinique74.51%7.170.78Martinique Black74.51%7.170.78Trinidad and Tobago0.00%0?Trinidad and Tobago Asian0.00%0?North America87.89%9.121.65Canada38.41%2.210.32Canada Amerindian38.41%2.210.32Mexico55.04%4.30.44Mexico Amerindian42.59%3.090.35Mexico Mestizo68.51%5.970.64United States88.10%9.171.68United States Amerindian42.79%3.310.35United States Asian78.84%8.030.95United States Austronesian58.09%5.470.48United States Black71.50%6.440.7United States Caucasoid90.15%9.682.03United States Hispanic72.95%6.90.74United States Mestizo72.23%6.780.72United States Polynesian73.18%5.870.75Central America49.91%4.060.4Costa Rica24.31%2.210.26Costa Rica Mestizo24.31%2.210.26Guatemala49.16%3.370.39Guatemala Amerindian49.16%3.370.39South America58.59%4.770.48Argentina62.67%5.360.54Argentina Amerindian45.78%3.40.37Argentina Caucasoid80.65%7.851.03Bolivia77.82%5.970.9Bolivia Amerindian77.82%5.970.9Brazil63.80%5.160.55Brazil Amerindian48.60%3.230.39Brazil Caucasoid84.39%8.811.28Brazil Mixed77.50%6.940.89Brazil Mulatto74.09%6.890.77Brazil Other0.00%0?Chile67.08%5.820.61Chile Amerindian72.65%6.090.73Chile Hispanic0.00%00Chile Mixed52.65%4.390.42Colombia54.02%4.340.43Colombia Amerindian47.40%3.650.38Colombia Black65.25%5.280.58Colombia Mestizo56.31%4.80.46Ecuador52.17%3.751.25Ecuador Amerindian52.17%3.751.25Ecuador Black0.00%00Paraguay4.90%0.290.63Paraguay Amerindian4.90%0.290.63Peru49.87%3.470.4Peru Amerindian49.87%3.470.4Peru Mestizo0.00%00Venezuela3.01%0.060.21Venezuela Amerindian0.00%00Venezuela Caucasoid0.00%0?Venezuela Mestizo0.00%0?Venezuela Mixed3.17%0.060.21Oceania59.87%5.380.5American Samoa0.00%0?American Samoa Polynesian0.00%0?Australia33.15%2.210.3Australia Australian Aborigines33.15%2.210.3Australia Caucasoid0.00%0?Chile67.08%5.820.61Chile Amerindian72.65%6.090.73Cook Islands78.59%6.440.93Cook Islands Polynesian78.59%6.440.93Fiji79.87%7.50.99Fiji Melanesian79.87%7.50.99Kiribati10.89%0.850.22Kiribati Micronesian10.89%0.850.22Nauru38.66%3.40.33Nauru Micronesian38.66%3.40.33New Caledonia81.41%8.443.77New Caledonia Melanesian81.41%8.443.77New Zealand84.46%6.761.29New Zealand Polynesian84.46%6.761.29Niue77.82%4.270.9Niue Polynesian77.82%4.270.9Papua New Guinea69.15%7.160.65Papua New Guinea Melanesian69.15%7.160.65Samoa80.86%7.291.04Samoa Polynesian80.86%7.291.04Tokelau55.11%2.820.45Tokelau Polynesian55.11%2.820.45Tonga71.91%6.120.71Tonga Polynesian71.91%6.120.71Average51.14%4.7?(Standard deviation)−32.55%−3.35(?)^a^Projected population coverage^b^Average number of epitope hits/HLA combinations recognized by the population^c^Minimum number of epitope hits/HLA combinations recognized by 90% of the population

According to the percentage of MHC-I E protein coverage, the world MHC-I represents 95.60%; 116 countries showed a higher percentage especially Chile Amerindian (100%), 23 other countries showed more than 4% but less than 50% while in East Asia it represents 94.80%, South Korea and South Oriental Korea (92.84%), China (88.77%), Iran and Iran Persian (91.53%%), Jordan and Jordan Arab (76.80%), Oman and Oman Arab (95.82%), Saudi Arabia and Saudi Arabia Arab (96.38%), Sudan (86.43%), Sudan Arab (49.41%), Sudan Black (0.00%), and Sudan Mixed (87.06%); *see* Table [8](#Tab8){ref-type="table"}. Iran Kurd, United Arab Emirates, and United Arab Emirates Arab were not mentioned and showed results in this tool.Table 8MHC-I coverage population for E proteinPopulation/AreaClass ICoverage^a^Average hit^b^PC90^c^World95.60%10.574.38East Asia94.80%10.932.58Japan96.19%11.443.12Japan Oriental96.19%11.443.12Korea, South92.84%10.412.16Korea, South Oriental92.84%10.412.16Mongolia94.37%10.073.12Mongolia Oriental94.37%10.073.12Northeast Asia88.80%9.380.89China88.77%9.330.89China Oriental88.77%9.330.89Hong Kong90.85%10.011.91Hong Kong Oriental90.85%10.011.91South Asia86.54%8.030.74India82.00%7.210.56India Asian82.00%7.210.56Pakistan88.63%8.741.76Pakistan Asian87.30%8.381.58Pakistan Mixed91.12%9.423.23Sri Lanka52.39%3.740.84Sri Lanka Asian52.39%3.740.84Southeast Asia87.81%9.990.82Indonesia76.44%7.80.42Indonesia Austronesian76.44%7.80.42Malaysia76.30%7.640.42Malaysia Austronesian40.59%3.170.34Malaysia Oriental84.44%9.020.64Philippines92.86%11.568.01Philippines Austronesian92.86%11.568.01Singapore85.74%9.040.7Singapore Austronesian82.82%8.550.58Singapore Oriental88.96%9.640.91Taiwan92.58%11.316.08Taiwan Oriental92.58%11.316.08Thailand82.85%7.460.58Thailand Oriental82.85%7.460.58Vietnam84.58%8.550.65Vietnam Oriental84.58%8.550.65Southwest Asia85.77%7.590.7Iran91.53%8.61.33Iran Persian91.53%8.61.33Israel82.14%7.290.56Israel Arab89.15%9.130.92Israel Jew87.17%7.840.78Jordan76.80%6.520.43Jordan Arab76.80%6.520.43Oman95.82%9.963.04Oman Arab95.82%9.963.04Saudi Arabia96.38%9.873.65Saudi Arabia Arab96.38%9.873.65Europe97.81%11.075.29Austria98.78%11.296Austria Caucasoid98.78%11.296Belgium98.75%10.626.02Belgium Caucasoid98.75%10.626.02Bulgaria96.59%11.084.52Bulgaria Caucasoid96.56%11.254.57Bulgaria Other97.43%10.024.35Croatia97.76%11.796.12Croatia Caucasoid97.76%11.796.12Czech Republic96.20%9.394.33Czech Republic Caucasoid96.20%9.394.33England99.29%11.436.21England Caucasoid99.29%11.436.21Finland99.80%12.567.8Finland Caucasoid99.80%12.567.8France98.05%10.724.75France Caucasoid98.05%10.724.75Georgia95.62%10.984.48Georgia Caucasoid97.22%11.666.21Georgia Kurd89.99%9.261Germany99.07%11.716.4Germany Caucasoid99.07%11.716.4Ireland Northern99.40%11.436.27Ireland Northern Caucasoid99.40%11.436.27Ireland South98.83%10.824.85Ireland South Caucasoid98.83%10.824.85Italy96.52%9.834.16Italy Caucasoid96.52%9.834.16Macedonia11.83%0.860.45Macedonia Caucasoid11.83%0.860.45Poland97.99%11.256.02Poland Caucasoid97.99%11.256.02Portugal97.11%10.984.73Portugal Caucasoid97.11%10.984.73Romania97.94%11.565.94Romania Caucasoid97.94%11.565.94Russia96.71%11.384.59Russia Other98.34%12.466.71Russia Siberian97.30%11.524.53Scotland15.91%0.810.24Scotland Caucasoid15.91%0.810.24Serbia43.75%0.780.18Serbia Caucasoid43.75%0.780.18Spain71.85%5.510.36Spain Caucasoid71.85%5.510.36Sweden99.69%12.616.84Sweden Caucasoid99.69%12.616.84Turkey44.80%3.581.45Turkey Caucasoid44.80%3.581.45East Africa86.99%6.960.77Kenya85.86%6.620.71Kenya Black85.86%6.620.71Uganda91.04%8.191.48Uganda Black91.04%8.191.48Zambia95.32%7.984.01Zambia Black95.32%7.984.01Zimbabwe91.57%7.691.71Zimbabwe Black91.57%7.691.71West Africa92.60%8.711.67Burkina Faso58.50%3.240.24Burkina Faso Black58.50%3.240.24Cape Verde96.69%10.094.14Cape Verde Black96.69%10.094.14Guinea-Bissau92.66%8.71.49Guinea-Bissau Black92.66%8.71.49Ivory Coast58.05%0.780.24Ivory Coast Black58.05%0.780.24Senegal95.03%9.114Senegal Black95.03%9.114Central Africa84.98%6.70.67Cameroon88.67%7.350.88Cameroon Black88.67%7.350.88Central African Republic10.75%0.270.11Central African Republic Black10.75%0.270.11Rwanda23.09%1.330.13Rwanda Black23.09%1.330.13Sao Tome and Principe95.54%8.722.29Sao Tome and Principe Black95.54%8.722.29North Africa91.87%8.611.86Mali94.28%8.821.74Mali Black94.28%8.821.74Morocco95.95%9.474.19Morocco Arab97.89%10.24.47Morocco Caucasoid94.32%8.964.02Sudan86.43%7.530.74Sudan Arab49.41%4.620.59Sudan Black0.00%00Sudan Mixed87.06%7.560.77Tunisia96.04%9.854.19Tunisia Arab96.04%9.854.19South Africa91.05%82.1South Africa91.05%82.1South Africa Black86.71%6.670.75South Africa Other93.82%9.592.73West Indies97.34%10.784.6Cuba97.20%10.654.53Cuba Caucasoid97.64%11.24.77Cuba Mulatto96.58%9.664.09Martinique22.56%2.031.16Martinique Black22.56%2.031.16North America96.88%10.984.65Mexico97.10%116.02Mexico Amerindian99.86%137.84Mexico Mestizo96.78%10.74.46United States96.93%10.984.66United States Amerindian99.44%13.158.19United States Asian92.39%10.322.29United States Black94.18%8.832.54United States Caucasoid98.65%11.46.08United States Hispanic97.46%11.014.77United States Mestizo98.09%11.24.97United States Polynesian97.53%11.573.62Central America5.10%0.160.11Guatemala5.10%0.160.11Guatemala Amerindian5.10%0.160.11South America86.24%8.010.73Argentina98.02%8.762.61Argentina Amerindian98.02%8.762.61Brazil93.72%9.432.69Brazil Amerindian92.35%8.372.16Brazil Caucasoid97.68%11.335.35Brazil Mixed95.06%9.853.75Chile94.93%10.634.37Chile Amerindian100.00%14.319.11Chile Mixed87.43%8.160.8Colombia9.86%0.760.67Colombia Black5.79%0.420.64Colombia Mestizo14.81%1.170.7Ecuador76.97%8.771.74Ecuador Amerindian76.97%8.771.74Peru99.98%13.698.37Peru Amerindian99.98%13.698.37Venezuela88.37%9.050.86Venezuela Amerindian88.88%8.980.9Venezuela Caucasoid9.18%0.830.99Venezuela Mestizo7.84%0.710.98Oceania91.82%10.924.06American Samoa95.26%12.147.15American Samoa Polynesian95.26%12.147.15Australia89.30%9.930.93Australia Australian Aborigines82.36%9.310.57Australia Caucasoid99.06%11.466.16Chile94.93%10.634.37Chile Amerindian100.00%14.319.11New Caledonia96.70%12.148.63New Caledonia Melanesian96.70%12.148.63Papua New Guinea97.26%12.588.57Papua New Guinea Melanesian97.26%12.588.57Average55.31%5.73?(Standard deviation)−44.16%−4.92(?)^a^Projected population coverage^b^Average number of epitope hits/HLA combinations recognized by the population^c^Minimum number of epitope hits/HLA combinations recognized by 90% of the population

According to the percentage of MHC-I modified E protein coverage population that represented 95.60% of the world population, 112 countries showed a higher percentile rate especially Chile Amerindian which represents 100.00%, 96 other countries showed 0% while in East Asia represents 94.80%, South Korea and South Oriental Korea (92.84%), China (88.77%), Iran (91.53%), Iran Persian (91.53%), Iran Kurd (0.00%), Jordan and Jordan Arab (76.80%), Oman and Oman Arab (95.82%), Saudi Arabia and Saudi Arabia Arab (96.38%), United Arab Emirates and United Arab Emirates Arab (0.0%), Sudan (60.56%), Sudan Arab (0.00%), Sudan Black (0.00%), and Sudan Mixed (60.56%); *see* Table [9](#Tab9){ref-type="table"}.Table 9MHC-I coverage population for modified E proteinPopulation/AreaClass ICoverage^a^Average hit^b^PC90^c^World95.60%10.574.38East Asia94.80%10.932.58Japan96.19%11.443.12Japan Oriental96.19%11.443.12Korea, South92.84%10.412.16Korea, South Oriental92.84%10.412.16Mongolia94.37%10.073.12Mongolia Oriental94.37%10.073.12Northeast Asia88.80%9.380.89China88.77%9.330.89China Oriental88.77%9.330.89Hong Kong90.85%10.011.91Hong Kong Oriental90.85%10.011.91South Asia86.54%8.030.74India82.00%7.210.56India Asian82.00%7.210.56Pakistan88.63%8.741.76Pakistan Asian87.30%8.381.58Pakistan Mixed91.12%9.423.23Sri Lanka52.39%3.740.84Sri Lanka Asian52.39%3.740.84Southeast Asia87.81%9.990.82Borneo0.00%0?Borneo Austronesian0.00%0?Indonesia76.44%7.80.42Indonesia Austronesian76.44%7.80.42Malaysia76.30%7.640.42Malaysia Austronesian40.59%3.170.34Malaysia Oriental84.44%9.020.64Philippines92.86%11.568.01Philippines Austronesian92.86%11.568.01Singapore85.74%9.040.7Singapore Austronesian82.82%8.550.58Singapore Oriental88.96%9.640.91Taiwan92.58%11.316.08Taiwan Oriental92.58%11.316.08Thailand82.85%7.460.58Thailand Oriental82.85%7.460.58Vietnam84.58%8.550.65Vietnam Oriental84.58%8.550.65Southwest Asia85.77%7.590.7Iran91.53%8.61.33Iran Kurd0.00%0?Iran Persian91.53%8.61.33Israel82.14%7.290.56Israel Arab89.15%9.130.92Israel Jew87.17%7.840.78Jordan76.80%6.520.43Jordan Arab76.80%6.520.43Lebanon0.00%00Lebanon Arab0.00%0?Lebanon Mixed0.00%00Oman95.82%9.963.04Oman Arab95.82%9.963.04Saudi Arabia96.38%9.873.65Saudi Arabia Arab96.38%9.873.65United Arab Emirates0.00%00United Arab Emirates Arab0.00%00Europe97.81%11.075.29Austria98.78%11.296Austria Caucasoid98.78%11.296Belarus0.00%0?Belarus Caucasoid0.00%0?Belgium98.75%10.626.02Belgium Caucasoid98.75%10.626.02Bulgaria96.59%11.084.52Bulgaria Caucasoid96.56%11.254.57Bulgaria Other97.43%10.024.35Croatia97.76%11.796.12Croatia Caucasoid97.76%11.796.12Czech Republic96.20%9.394.33Czech Republic Caucasoid96.20%9.394.33Czech Republic Other0.00%0?Denmark0.00%00Denmark Caucasoid0.00%00England99.29%11.436.21England Caucasoid99.29%11.436.21England Jew0.00%00England Mixed0.00%0?Finland99.80%12.567.8Finland Caucasoid99.80%12.567.8France98.05%10.724.75France Caucasoid98.05%10.724.75Georgia95.62%10.984.48Georgia Caucasoid97.22%11.666.21Georgia Kurd89.99%9.261Germany99.07%11.716.4Germany Caucasoid99.07%11.716.4Greece0.00%0?Greece Caucasoid0.00%0?Ireland Northern99.40%11.436.27Ireland Northern Caucasoid99.40%11.436.27Ireland South98.83%10.824.85Ireland South Caucasoid98.83%10.824.85Italy96.52%9.834.16Italy Caucasoid96.52%9.834.16Macedonia11.83%0.860.45Macedonia Caucasoid11.83%0.860.45Netherlands0.00%0?Netherlands Caucasoid0.00%0?Norway0.00%0?Norway Caucasoid0.00%0?Poland97.99%11.256.02Poland Caucasoid97.99%11.256.02Portugal97.11%10.984.73Portugal Caucasoid97.11%10.984.73Romania97.94%11.565.94Romania Caucasoid97.94%11.565.94Russia96.71%11.384.59Russia Caucasoid0.00%00Russia Mixed0.00%00Russia Other98.34%12.466.71Russia Siberian97.30%11.524.53Scotland15.91%0.810.24Scotland Caucasoid15.91%0.810.24Serbia43.75%0.780.18Serbia Caucasoid43.75%0.780.18Slovakia0.00%0?Slovakia Caucasoid0.00%0?Slovenia0.00%0?Slovenia Caucasoid0.00%0?Spain71.85%5.510.36Spain Caucasoid71.85%5.510.36Spain Jew0.00%0?Spain Other0.00%0?Sweden99.69%12.616.84Sweden Caucasoid99.69%12.616.84Switzerland0.00%00Switzerland Caucasoid0.00%00Turkey44.80%3.581.45Turkey Caucasoid44.80%3.581.45Ukraine0.00%0?Ukraine Caucasoid0.00%0?United Kingdom0.00%00United Kingdom Caucasoid0.00%00Wales0.00%00Wales Caucasoid0.00%00East Africa86.99%6.960.77Kenya85.86%6.620.71Kenya Black85.86%6.620.71Uganda91.04%8.191.48Uganda Black91.04%8.191.48Zambia95.32%7.984.01Zambia Black95.32%7.984.01Zimbabwe91.57%7.691.71Zimbabwe Black91.57%7.691.71West Africa92.60%8.711.67Burkina Faso58.50%3.240.24Burkina Faso Black58.50%3.240.24Cape Verde96.69%10.094.14Cape Verde Black96.69%10.094.14Gambia0.00%0?Gambia Black0.00%0?Ghana0.00%00Ghana Black0.00%00Guinea-Bissau92.66%8.71.49Guinea-Bissau Black92.66%8.71.49Ivory Coast58.05%0.780.24Ivory Coast Black58.05%0.780.24Liberia0.00%0?Liberia Black0.00%0?Nigeria0.00%0?Nigeria Black0.00%0?Senegal95.03%9.114Senegal Black95.03%9.114Central Africa84.98%6.70.67Cameroon88.67%7.350.88Cameroon Black88.67%7.350.88Central African Republic10.75%0.270.11Central African Republic Black10.75%0.270.11Congo0.00%0?Congo Black0.00%0?Equatorial Guinea0.00%00Equatorial Guinea Black0.00%00Gabon0.00%0?Gabon Black0.00%0?Rwanda23.09%1.330.13Rwanda Black23.09%1.330.13Sao Tome and Principe95.54%8.722.29Sao Tome and Principe Black95.54%8.722.29North Africa91.87%8.611.86Algeria0.00%0?Algeria Arab0.00%0?Ethiopia0.00%0?Ethiopia Black0.00%0?Mali94.28%8.821.74Mali Black94.28%8.821.74Morocco95.95%9.474.19Morocco Arab97.89%10.24.47Morocco Caucasoid94.32%8.964.02Sudan86.43%7.530.74Sudan Arab49.41%4.620.59Sudan Black0.00%00Sudan Mixed87.06%7.560.77Tunisia96.04%9.854.19Tunisia Arab96.04%9.854.19Tunisia Berber0.00%0?South Africa91.05%82.1South Africa91.05%82.1South Africa Black86.71%6.670.75South Africa Other93.82%9.592.73West Indies97.34%10.784.6Cuba97.20%10.654.53Cuba Caucasoid97.64%11.24.77Cuba Mixed0.00%0?Cuba Mulatto96.58%9.664.09Jamaica0.00%0?Jamaica Black0.00%0?Martinique22.56%2.031.16Martinique Black22.56%2.031.16Trinidad and Tobago0.00%00Trinidad and Tobago Asian0.00%00North America96.88%10.984.65Canada0.00%0?Canada Amerindian0.00%0?Mexico97.10%116.02Mexico Amerindian99.86%137.84Mexico Mestizo96.78%10.74.46United States96.93%10.984.66United States Amerindian99.44%13.158.19United States Asian92.39%10.322.29United States Austronesian0.00%0?United States Black94.18%8.832.54United States Caucasoid98.65%11.46.08United States Hispanic97.46%11.014.77United States Mestizo98.09%11.24.97United States Polynesian97.53%11.573.62Central America5.10%0.160.11Costa Rica0.00%0?Costa Rica Mestizo0.00%0?Guatemala5.10%0.160.11Guatemala Amerindian5.10%0.160.11South America86.24%8.010.73Argentina98.02%8.762.61Argentina Amerindian98.02%8.762.61Argentina Caucasoid0.00%0?Bolivia0.00%0?Bolivia Amerindian0.00%0?Brazil93.72%9.432.69Brazil Amerindian92.35%8.372.16Brazil Caucasoid97.68%11.335.35Brazil Mixed95.06%9.853.75Brazil Mulatto0.00%0?Brazil Other0.00%00Chile94.93%10.634.37Chile Amerindian100.00%14.319.11Chile Hispanic0.00%0?Chile Mixed87.43%8.160.8Colombia9.86%0.760.67Colombia Amerindian0.00%00Colombia Black5.79%0.420.64Colombia Mestizo14.81%1.170.7Ecuador76.97%8.771.74Ecuador Amerindian76.97%8.771.74Ecuador Black0.00%0?Paraguay0.00%0?Paraguay Amerindian0.00%0?Peru99.98%13.698.37Peru Amerindian99.98%13.698.37Peru Mestizo0.00%00Venezuela88.37%9.050.86Venezuela Amerindian88.88%8.980.9Venezuela Caucasoid9.18%0.830.99Venezuela Mestizo7.84%0.710.98Venezuela Mixed0.00%0?Oceania91.82%10.924.06American Samoa95.26%12.147.15American Samoa Polynesian95.26%12.147.15Australia89.30%9.930.93Australia Australian Aborigines82.36%9.310.57Australia Caucasoid99.06%11.466.16Chile94.93%10.634.37Chile Amerindian100.00%14.319.11Cook Islands0.00%0?Cook Islands Polynesian0.00%0?Fiji0.00%0?Fiji Melanesian0.00%0?Kiribati0.00%0?Kiribati Micronesian0.00%0?Nauru0.00%0?Nauru Micronesian0.00%0?New Caledonia96.70%12.148.63New Caledonia Melanesian96.70%12.148.63New Zealand0.00%0?New Zealand Polynesian0.00%0?Niue0.00%0?Niue Polynesian0.00%0?Papua New Guinea97.26%12.588.57Papua New Guinea Melanesian97.26%12.588.57Samoa0.00%0?Samoa Polynesian0.00%0?Tokelau0.00%0?Tokelau Polynesian0.00%0?Tonga0.00%0?Tonga Polynesian0.00%0?Average55.31%5.73?(Standard deviation)−44.16%−4.92(?)^a^Projected population coverage^b^Average number of epitope hits/HLA combinations recognized by the population^c^Minimum number of epitope hits/HLA combinations recognized by 90% of the population

According to the percentile rates of MHC-II E protein coverage population that represented 81.81% of the world population, 63 countries showed a higher percentage especially Norway and Norway Caucasoid (94.71%), 45 other countries showed from 0% to less than 50% while in East Asia represents 94.80%, South Korea and South Oriental Korea (85.32%), China (59.99%), Iran (64.22%), Iran Persian (65.72%), Iran Kurd (55.78%), Saudi Arabia and Saudi Arabia Arab (80.14%), United Arab Emirates and United Arab Emirates Arab (32.92%), and Sudan and Sudan Mixed (60.56%); *see* Table [10](#Tab10){ref-type="table"}. Oman, Jordan, Sudan Black, and Arab were not mentioned and showed results in this tool.Table 10The MHC-II coverage population for E proteinPopulation/AreaClass IICoverage^a^Average hit^b^PC90^c^World81.81%8.161.1East Asia81.82%8.831.1Japan74.83%7.850.79Japan Oriental74.83%7.850.79Korea, South85.32%9.561.36Korea, South Oriental85.32%9.561.36Mongolia81.85%7.791.1Mongolia Oriental81.85%7.791.1Northeast Asia59.99%5.330.5China59.99%5.330.5China Oriental59.99%5.330.5South Asia75.38%7.40.81India74.99%7.350.8India Asian74.99%7.350.8Pakistan1.18%0.090.81Pakistan Asian1.45%0.120.81Southeast Asia56.98%4.980.46Borneo49.02%4.030.39Borneo Austronesian49.02%4.030.39Indonesia47.84%4.40.38Indonesia Austronesian47.84%4.40.38Malaysia57.99%5.340.48Malaysia Austronesian55.38%5.120.45Malaysia Oriental70.35%6.570.67Philippines28.56%2.520.28Philippines Austronesian28.56%2.520.28Singapore65.78%6.040.58Singapore Austronesian65.78%6.040.58Singapore Oriental0.00%0?Taiwan67.88%6.130.62Taiwan Oriental67.88%6.130.62Thailand63.90%5.920.55Thailand Oriental63.90%5.920.55Vietnam54.44%4.430.44Vietnam Oriental54.44%4.430.44Southwest Asia43.93%3.650.36Iran64.22%5.650.56Iran Kurd55.78%4.740.45Iran Persian65.72%5.830.58Israel68.79%6.40.64Israel Arab67.51%6.20.62Israel Jew69.65%6.510.66Jordan52.88%4.560.42Jordan Arab52.88%4.560.42Lebanon70.46%6.480.68Lebanon Arab70.46%6.480.68Saudi Arabia80.14%8.311.01Saudi Arabia Arab80.14%8.311.01United Arab Emirates32.92%0.660.3United Arab Emirates Arab32.92%0.660.3Europe85.83%8.881.41Austria93.34%10.82.82Austria Caucasoid93.34%10.82.82Belarus43.81%3.551.25Belarus Caucasoid43.81%3.551.25Belgium79.39%7.160.97Belgium Caucasoid79.39%7.160.97Bulgaria57.23%4.950.47Bulgaria Caucasoid57.23%4.950.47Croatia66.71%5.890.6Croatia Caucasoid66.71%5.890.6Czech Republic86.21%9.231.45Czech Republic Caucasoid88.76%9.661.78Czech Republic Other64.14%6.40.56Denmark88.98%9.041.81Denmark Caucasoid88.98%9.041.81England93.48%10.492.74England Caucasoid93.48%10.492.74Finland51.14%4.240.41Finland Caucasoid51.14%4.240.41France88.54%9.291.74France Caucasoid88.54%9.291.74Georgia75.05%7.090.8Georgia Caucasoid75.05%7.090.8Germany91.14%10.142.26Germany Caucasoid91.14%10.142.26Greece66.92%6.290.6Greece Caucasoid66.92%6.290.6Ireland Northern94.65%10.582.89Ireland Northern Caucasoid94.65%10.582.89Ireland South93.15%102.51Ireland South Caucasoid93.15%102.51Italy85.90%5.931.42Italy Caucasoid85.90%5.931.42Macedonia66.53%6.20.6Macedonia Caucasoid66.53%6.20.6Netherlands83.44%8.331.21Netherlands Caucasoid83.44%8.331.21Norway94.71%10.563.01Norway Caucasoid94.71%10.563.01Poland84.46%8.851.29Poland Caucasoid84.46%8.851.29Portugal78.00%7.740.91Portugal Caucasoid78.00%7.740.91Russia77.62%7.240.89Russia Caucasoid88.52%9.811.74Russia Other85.01%9.21.33Russia Siberian78.83%7.140.94Scotland90.82%10.12.2Scotland Caucasoid90.82%10.12.2Slovakia18.28%0.370.24Slovakia Caucasoid18.28%0.370.24Slovenia84.85%8.741.32Slovenia Caucasoid84.85%8.741.32Spain80.51%8.281.03Spain Caucasoid80.84%8.341.04Spain Other6.30%0.570.96Sweden88.07%9.131.68Sweden Caucasoid88.07%9.131.68Turkey76.19%7.30.84Turkey Caucasoid76.19%7.30.84Ukraine50.64%4.171.42Ukraine Caucasoid50.64%4.171.42East Africa68.30%5.650.63Zimbabwe68.30%5.650.63Zimbabwe Black68.30%5.650.63West Africa65.23%6.130.58Cape Verde80.38%8.11.02Cape Verde Black80.38%8.11.02Guinea-Bissau71.16%7.040.69Guinea-Bissau Black71.16%7.040.69Senegal30.28%2.320.29Senegal Black30.28%2.320.29Central Africa62.71%5.170.54Cameroon49.87%3.310.4Cameroon Black49.87%3.310.4Central African Republic82.69%6.471.16Central African Republic Black82.69%6.471.16Congo68.66%5.930.64Congo Black68.66%5.930.64Equatorial Guinea47.58%3.550.38Equatorial Guinea Black47.58%3.550.38Gabon41.78%3.841.2Gabon Black41.78%3.841.2Rwanda62.79%5.380.54Rwanda Black62.79%5.380.54Sao Tome and Principe66.50%4.890.6Sao Tome and Principe Black66.50%4.890.6North Africa75.06%70.8Algeria77.15%7.250.88Algeria Arab77.15%7.250.88Ethiopia83.00%8.711.18Ethiopia Black83.00%8.711.18Morocco83.44%8.141.21Morocco Arab85.07%8.251.34Morocco Caucasoid79.75%8.070.99Sudan60.56%4.520.51Sudan Mixed60.56%4.520.51Tunisia74.26%6.820.78Tunisia Arab74.97%6.780.8Tunisia Berber74.47%7.430.78South Africa32.10%1.110.29South Africa32.10%1.110.29South Africa Black32.10%1.110.29West Indies69.22%6.670.65Cuba85.48%9.661.38Cuba Mixed85.48%9.661.38Jamaica27.41%2.280.28Jamaica Black27.41%2.280.28Martinique74.51%7.170.78Martinique Black74.51%7.170.78North America87.89%9.121.65Canada38.41%2.210.32Canada Amerindian38.41%2.210.32Mexico55.04%4.30.44Mexico Amerindian42.59%3.090.35Mexico Mestizo68.51%5.970.64United States88.10%9.171.68United States Amerindian42.79%3.310.35United States Asian78.84%8.030.95United States Austronesian58.09%5.470.48United States Black71.50%6.440.7United States Caucasoid90.15%9.682.03United States Hispanic72.95%6.90.74United States Mestizo72.23%6.780.72United States Polynesian73.18%5.870.75Central America49.91%4.060.4Costa Rica24.31%2.210.26Costa Rica Mestizo24.31%2.210.26Guatemala49.16%3.370.39Guatemala Amerindian49.16%3.370.39South America58.59%4.770.48Argentina62.67%5.360.54Argentina Amerindian45.78%3.40.37Argentina Caucasoid80.65%7.851.03Bolivia77.82%5.970.9Bolivia Amerindian77.82%5.970.9Brazil63.80%5.160.55Brazil Amerindian48.60%3.230.39Brazil Caucasoid84.39%8.811.28Brazil Mixed77.50%6.940.89Brazil Mulatto74.09%6.890.77Chile67.08%5.820.61Chile Amerindian72.65%6.090.73Chile Mixed52.65%4.390.42Colombia54.02%4.340.43Colombia Amerindian47.40%3.650.38Colombia Black65.25%5.280.58Colombia Mestizo56.31%4.80.46Ecuador52.17%3.751.25Ecuador Amerindian52.17%3.751.25Paraguay4.90%0.290.63Paraguay Amerindian4.90%0.290.63Peru49.87%3.470.4Peru Amerindian49.87%3.470.4Venezuela3.01%0.060.21Venezuela Mixed3.17%0.060.21Oceania59.87%5.380.5Australia33.15%2.210.3Australia Australian Aborigines33.15%2.210.3Chile67.08%5.820.61Chile Amerindian72.65%6.090.73Cook Islands78.59%6.440.93Cook Islands Polynesian78.59%6.440.93Fiji79.87%7.50.99Fiji Melanesian79.87%7.50.99Kiribati10.89%0.850.22Kiribati Micronesian10.89%0.850.22Nauru38.66%3.40.33Nauru Micronesian38.66%3.40.33New Caledonia81.41%8.443.77New Caledonia Melanesian81.41%8.443.77New Zealand84.46%6.761.29New Zealand Polynesian84.46%6.761.29Niue77.82%4.270.9Niue Polynesian77.82%4.270.9Papua New Guinea69.15%7.160.65Papua New Guinea Melanesian69.15%7.160.65Samoa80.86%7.291.04Samoa Polynesian80.86%7.291.04Tokelau55.11%2.820.45Tokelau Polynesian55.11%2.820.45Tonga71.91%6.120.71Tonga Polynesian71.91%6.120.71Average51.14%4.7?(Standard deviation)−32.55%−3.35(?)^a^Projected population coverage^b^Average number of epitope hits/HLA combinations recognized by the population^c^Minimum number of epitope hits/HLA combinations recognized by 90% of the population

According to the percentage of MHC-II modified E protein coverage population that represented 81.81% of the world population, 62 countries showed a higher percentage especially Norway and Norway Caucasoid (94.71%), 59 other countries showed 0% while in East Asia represents 94.80%, South Korea and South Oriental Korea (85.32%), China (59.99%), Iran (64.22%), Iran Persian (65.72%), Iran Kurd (55.78%), Jordan and Jordan Arab (52.88%), Oman and Oman Arab (0.00%), Saudi Arabia and Saudi Arabia Arab (80.14%), United Arab Emirates and United Arab Emirates Arab (32.92%), Sudan and Sudan Mixed (60.56%), and Sudan Arab and Sudan Black (0.00%); *see* Table [11](#Tab11){ref-type="table"}.Table 11The MHC-II coverage population for modified E proteinPopulation/AreaClass IICoverage^a^Average hit^b^PC90^c^World81.81%8.161.1East Asia81.82%8.831.1Japan74.83%7.850.79Japan Oriental74.83%7.850.79Korea, South85.32%9.561.36Korea, South Oriental85.32%9.561.36Mongolia81.85%7.791.1Mongolia Oriental81.85%7.791.1Northeast Asia59.99%5.330.5China59.99%5.330.5China Oriental59.99%5.330.5Hong Kong0.00%0?Hong Kong Oriental0.00%0?South Asia75.38%7.40.81India74.99%7.350.8India Asian74.99%7.350.8Pakistan1.18%0.090.81Pakistan Asian1.45%0.120.81Pakistan Mixed0.00%00Sri Lanka0.00%0?Sri Lanka Asian0.00%0?Southeast Asia56.98%4.980.46Borneo49.02%4.030.39Borneo Austronesian49.02%4.030.39Indonesia47.84%4.40.38Indonesia Austronesian47.84%4.40.38Malaysia57.99%5.340.48Malaysia Austronesian55.38%5.120.45Malaysia Oriental70.35%6.570.67Philippines28.56%2.520.28Philippines Austronesian28.56%2.520.28Singapore65.78%6.040.58Singapore Austronesian65.78%6.040.58Singapore Oriental0.00%0?Taiwan67.88%6.130.62Taiwan Oriental67.88%6.130.62Thailand63.90%5.920.55Thailand Oriental63.90%5.920.55Vietnam54.44%4.430.44Vietnam Oriental54.44%4.430.44Southwest Asia43.93%3.650.36Iran64.22%5.650.56Iran Kurd55.78%4.740.45Iran Persian65.72%5.830.58Israel68.79%6.40.64Israel Arab67.51%6.20.62Israel Jew69.65%6.510.66Jordan52.88%4.560.42Jordan Arab52.88%4.560.42Lebanon70.46%6.480.68Lebanon Arab70.46%6.480.68Lebanon Mixed0.00%0?Oman0.00%0?Oman Arab0.00%0?Saudi Arabia80.14%8.311.01Saudi Arabia Arab80.14%8.311.01United Arab Emirates32.92%0.660.3United Arab Emirates Arab32.92%0.660.3Europe85.83%8.881.41Austria93.34%10.82.82Austria Caucasoid93.34%10.82.82Belarus43.81%3.551.25Belarus Caucasoid43.81%3.551.25Belgium79.39%7.160.97Belgium Caucasoid79.39%7.160.97Bulgaria57.23%4.950.47Bulgaria Caucasoid57.23%4.950.47Bulgaria Other0.00%0?Croatia66.71%5.890.6Croatia Caucasoid66.71%5.890.6Czech Republic86.21%9.231.45Czech Republic Caucasoid88.76%9.661.78Czech Republic Other64.14%6.40.56Denmark88.98%9.041.81Denmark Caucasoid88.98%9.041.81England93.48%10.492.74England Caucasoid93.48%10.492.74England Jew0.00%0?England Mixed0.00%00Finland51.14%4.240.41Finland Caucasoid51.14%4.240.41France88.54%9.291.74France Caucasoid88.54%9.291.74Georgia75.05%7.090.8Georgia Caucasoid75.05%7.090.8Georgia Kurd0.00%0?Germany91.14%10.142.26Germany Caucasoid91.14%10.142.26Greece66.92%6.290.6Greece Caucasoid66.92%6.290.6Ireland Northern94.65%10.582.89Ireland Northern Caucasoid94.65%10.582.89Ireland South93.15%102.51Ireland South Caucasoid93.15%102.51Italy85.90%5.931.42Italy Caucasoid85.90%5.931.42Macedonia66.53%6.20.6Macedonia Caucasoid66.53%6.20.6Netherlands83.44%8.331.21Netherlands Caucasoid83.44%8.331.21Norway94.71%10.563.01Norway Caucasoid94.71%10.563.01Poland84.46%8.851.29Poland Caucasoid84.46%8.851.29Portugal78.00%7.740.91Portugal Caucasoid78.00%7.740.91Romania0.00%0?Romania Caucasoid0.00%0?Russia77.62%7.240.89Russia Caucasoid88.52%9.811.74Russia Mixed0.00%00Russia Other85.01%9.21.33Russia Siberian78.83%7.140.94Scotland90.82%10.12.2Scotland Caucasoid90.82%10.12.2Serbia0.00%0?Serbia Caucasoid0.00%0?Slovakia18.28%0.370.24Slovakia Caucasoid18.28%0.370.24Slovenia84.85%8.741.32Slovenia Caucasoid84.85%8.741.32Spain80.51%8.281.03Spain Caucasoid80.84%8.341.04Spain Jew0.00%0?Spain Other6.30%0.570.96Sweden88.07%9.131.68Sweden Caucasoid88.07%9.131.68Switzerland0.00%0?Switzerland Caucasoid0.00%0?Turkey76.19%7.30.84Turkey Caucasoid76.19%7.30.84Ukraine50.64%4.171.42Ukraine Caucasoid50.64%4.171.42United Kingdom0.00%00United Kingdom Caucasoid0.00%00Wales0.00%00Wales Caucasoid0.00%00East Africa68.30%5.650.63Kenya0.00%00Kenya Black0.00%00Uganda0.00%00Uganda Black0.00%00Zambia0.00%0?Zambia Black0.00%0?Zimbabwe68.30%5.650.63Zimbabwe Black68.30%5.650.63West Africa65.23%6.130.58Burkina Faso0.00%0?Burkina Faso Black0.00%0?Cape Verde80.38%8.11.02Cape Verde Black80.38%8.11.02Gambia0.00%00Gambia Black0.00%00Ghana0.00%0?Ghana Black0.00%0?Guinea-Bissau71.16%7.040.69Guinea-Bissau Black71.16%7.040.69Ivory Coast0.00%0?Ivory Coast Black0.00%0?Liberia0.00%00Liberia Black0.00%00Nigeria0.00%00Nigeria Black0.00%00Senegal30.28%2.320.29Senegal Black30.28%2.320.29Central Africa62.71%5.170.54Cameroon49.87%3.310.4Cameroon Black49.87%3.310.4Central African Republic82.69%6.471.16Central African Republic Black82.69%6.471.16Congo68.66%5.930.64Congo Black68.66%5.930.64Equatorial Guinea47.58%3.550.38Equatorial Guinea Black47.58%3.550.38Gabon41.78%3.841.2Gabon Black41.78%3.841.2Rwanda62.79%5.380.54Rwanda Black62.79%5.380.54Sao Tome and Principe66.50%4.890.6Sao Tome and Principe Black66.50%4.890.6North Africa75.06%70.8Algeria77.15%7.250.88Algeria Arab77.15%7.250.88Ethiopia83.00%8.711.18Ethiopia Black83.00%8.711.18Mali0.00%0?Mali Black0.00%0?Morocco83.44%8.141.21Morocco Arab85.07%8.251.34Morocco Caucasoid79.75%8.070.99Sudan60.56%4.520.51Sudan Arab0.00%0?Sudan Black0.00%00Sudan Mixed60.56%4.520.51Tunisia74.26%6.820.78Tunisia Arab74.97%6.780.8Tunisia Berber74.47%7.430.78South Africa32.10%1.110.29South Africa32.10%1.110.29South Africa Black32.10%1.110.29South Africa Other0.00%0?West Indies69.22%6.670.65Cuba85.48%9.661.38Cuba Caucasoid0.00%0?Cuba Mixed85.48%9.661.38Cuba Mulatto0.00%0?Jamaica27.41%2.280.28Jamaica Black27.41%2.280.28Martinique74.51%7.170.78Martinique Black74.51%7.170.78Trinidad and Tobago0.00%0?Trinidad and Tobago Asian0.00%0?North America87.89%9.121.65Canada38.41%2.210.32Canada Amerindian38.41%2.210.32Mexico55.04%4.30.44Mexico Amerindian42.59%3.090.35Mexico Mestizo68.51%5.970.64United States88.10%9.171.68United States Amerindian42.79%3.310.35United States Asian78.84%8.030.95United States Austronesian58.09%5.470.48United States Black71.50%6.440.7United States Caucasoid90.15%9.682.03United States Hispanic72.95%6.90.74United States Mestizo72.23%6.780.72United States Polynesian73.18%5.870.75Central America49.91%4.060.4Costa Rica24.31%2.210.26Costa Rica Mestizo24.31%2.210.26Guatemala49.16%3.370.39Guatemala Amerindian49.16%3.370.39South America58.59%4.770.48Argentina62.67%5.360.54Argentina Amerindian45.78%3.40.37Argentina Caucasoid80.65%7.851.03Bolivia77.82%5.970.9Bolivia Amerindian77.82%5.970.9Brazil63.80%5.160.55Brazil Amerindian48.60%3.230.39Brazil Caucasoid84.39%8.811.28Brazil Mixed77.50%6.940.89Brazil Mulatto74.09%6.890.77Brazil Other0.00%0?Chile67.08%5.820.61Chile Amerindian72.65%6.090.73Chile Hispanic0.00%00Chile Mixed52.65%4.390.42Colombia54.02%4.340.43Colombia Amerindian47.40%3.650.38Colombia Black65.25%5.280.58Colombia Mestizo56.31%4.80.46Ecuador52.17%3.751.25Ecuador Amerindian52.17%3.751.25Ecuador Black0.00%00Paraguay4.90%0.290.63Paraguay Amerindian4.90%0.290.63Peru49.87%3.470.4Peru Amerindian49.87%3.470.4Peru Mestizo0.00%00Venezuela3.01%0.060.21Venezuela Amerindian0.00%00Venezuela Caucasoid0.00%0?Venezuela Mestizo0.00%0?Venezuela Mixed3.17%0.060.21Oceania59.87%5.380.5American Samoa0.00%0?American Samoa Polynesian0.00%0?Australia33.15%2.210.3Australia Australian Aborigines33.15%2.210.3Australia Caucasoid0.00%0?Chile67.08%5.820.61Chile Amerindian72.65%6.090.73Cook Islands78.59%6.440.93Cook Islands Polynesian78.59%6.440.93Fiji79.87%7.50.99Fiji Melanesian79.87%7.50.99Kiribati10.89%0.850.22Kiribati Micronesian10.89%0.850.22Nauru38.66%3.40.33Nauru Micronesian38.66%3.40.33New Caledonia81.41%8.443.77New Caledonia Melanesian81.41%8.443.77New Zealand84.46%6.761.29New Zealand Polynesian84.46%6.761.29Niue77.82%4.270.9Niue Polynesian77.82%4.270.9Papua New Guinea69.15%7.160.65Papua New Guinea Melanesian69.15%7.160.65Samoa80.86%7.291.04Samoa Polynesian80.86%7.291.04Tokelau55.11%2.820.45Tokelau Polynesian55.11%2.820.45Tonga71.91%6.120.71Tonga Polynesian71.91%6.120.71Average51.14%4.7?(Standard deviation)−32.55%−3.35(?)^a^Projected population coverage^b^Average number of epitope hits/HLA combinations recognized by the population^c^Minimum number of epitope hits/HLA combinations recognized by 90% of the population

Homology Modeling {#Sec55}
-----------------

The results of homology modeling were not shown here because they are not necessary.

Confirmation of Amino Acid Change in Spike Glycoprotein (S) and Envelope Protein (E) Sequence {#Sec56}
---------------------------------------------------------------------------------------------

The results of confirmatory amino acid change were not shown here because they are not necessary.

Peptide Search Tool {#Sec57}
-------------------

The results of peptide search tool showed presence of selected peptide sequence in another organisms such as *Leishmania donovani*, *Drosophila sechellia* (fruit fly), *Leishmania infantum*, *Trypanosoma cruzi* Dm28c, *Strigamia maritime*, and *Nocardioides dokdonensis*; besides some species of , *Salmonella*, *Streptococcus*, these may mean the presence of these peptides in those organisms had a relationship with respiratory disease but still needs to go deeper to confirm this suggestion, other things we can easily synthesis the desired peptides in laboratory by using one of these organisms (cloning techniques) because it is easy and no risk from acquired a very dangers infections beside determination of the peptide sequences impact on immune system via injected laboratory animals with those selected peptide sequences from any organisms.

AllerHunter: Cross-Reactive Allergen Prediction Program {#Sec58}
-------------------------------------------------------

Any sequence can be considered as a cross-reactive allergen if its probability is ≧0.06. The results considered that envelope (E) protein, spike (S) glycoprotein, and modified S glycoprotein are potential non-allergens with scores of 0.01, 0.0, and 0.0, respectively, while modified E protein sequence was too short for prediction (AllerHunter predicted the query sequence as a potential allergen with score of 0.07). According to the FAO/WHO, E and modified E protein sequences are classified as a non-allergen because they do not meet the criteria set by the FAO/WHO evaluation scheme for cross-reactive allergen prediction, but in S and modified S glycoprotein, they are classified as a potential allergen based on the FAO/WHO evaluation scheme because query sequence matches at least one sequence in the AllerHunter data set with at least 35 percent identity over 80 amino acids.

AlgPred: Prediction of Allergenic Proteins and Mapping of IgE Epitopes {#Sec59}
----------------------------------------------------------------------

AlgPred showed non**-**allergen for all four sequences (S, E, modified S and E proteins) as follows:Prediction by mapping of IgE epitope: The protein sequence does not contain experimentally proven IgE epitope.MAST RESULT: No Hits found; NON ALLERGEN.BLAST results of ARPS: No hits found, NON-ALLERGEN.Prediction by hybrid approach: NON-ALLERGEN/ALLERGEN.

There were slightly differences between the four sequences in SVM prediction methods according to amino acid composition/dipeptide composition as in Tables [12](#Tab12){ref-type="table"} and [13](#Tab13){ref-type="table"}.Table 12SVM prediction methods based on amino acid composition for the four protein sequencesTypes of protein sequenceSVM prediction based on amino acid compositionScoreThresholdPositive predictive valueNegative predictive valueS glycoproteinAllergen0.014762929−0.470.05%80.74%Modified S glycoproteinAllergen0.0065929692−0.470.05%80.74%E proteinAllergen−0.3638541−0.447.13%/89.71%Modified E proteinNon-allergen−1.08932−0.415.19%94.18%.Table 13Illustrates SVM prediction methods based on dipeptide composition for the four protein sequencesTypes of protein sequenceSVM prediction based on amino acid compositionScoreThresholdPositive predictive valueNegative predictive valueS glycoproteinAllergen−0.04096577−0.263.1%85.56%Modified S glycoproteinAllergen−0.059498832−0.263.1%85.56%E proteinNon-allergen−0.7511982−0.213.26%74.19%Modified E proteinNon-allergen−0.65278098−0.213.26%74.19%

VaxiJen v2.0 {#Sec60}
------------

VaxJen servers showed three protein sequences out of two, considered as probable antigens, as illustrated below:

S glycoprotein: threshold for this model, 0.4; overall antigen prediction, 0.4827 (probable ANTIGEN).

Modified S glycoprotein: threshold for this model, 0.4; overall antigen prediction, 0.4907 (probable ANTIGEN).

E protein: threshold for this model, 0.4; overall antigen prediction, 0.3811 (probable NON-ANTIGEN).

Modified E protein: threshold for this model, 0.4; overall antigen prediction, 0.4417 (probable ANTIGEN).

Discussions {#Sec61}
===========

Today, there are so many different ways to develop MERS-CoV vaccine; some of them partially succeed but the others failed while the remaining nor succeed neither failed because it depends on software program for different reasons and still need to go under vaccine protocols processing, in those studies that consist with S1 protein subunit especially RBD (the most mutable region that containing mutation sites which define antibody escape variants) was considered the basis for several MERS-CoV vaccine candidates in many studies such as using RBD with aluminum salt or oil-in-water adjuvants; can elicited neutralizing antibodies of high potency across multiple viral strains by Modjarrad \[[@CR4]\] and Wang et al. \[[@CR6]\] said that the full-length S DNA and a truncated S1 subunit glycoprotein can elicit a higher titer of neutralizing antibodies; this kind of immunization protected non-human primates (NHPs) from severe lung disease after intratracheal challenge with MERS-CoV injection; in another study that was done in Iran by Poorinmohammad et al. \[[@CR15]\] \[NetCTL 1.2 (Larsen et al., 2007), EpiJen (Doytchinova et al, 2006), and NHLApred (Bhasin and Raghava, 2007), they were selected computational prediction tools with PEPstr server for modeling (Kaur et al., 2007)\] to identify cytotoxic T-lymphocyte epitopes presented by the human leukocyte antigen (HLA)-A∗0201; as this is the most frequent HLA class I allele among Middle Eastern populations with this selected RBD for their study, they showed LLSGTPPQV, ILDYFSYPL ILATVPHNL, NLTTITKPL, LQMGFGITV, and FSNPTCLIL as selected epitopes but LLSGTPPQV and FSNPTCLIL were considered as real epitope due to the following: peptides with binding orientations closer to the native structure and lower binding free energy scores are ranked higher in having the potential to be real epitopes reverse another study were done by Shi J et al. \[[@CR19]\] by using the Immune Epitope Database, that said: the nucleocapsid (N) protein of MERS-CoV might be a better protective immunogen with high conservancy and potential eliciting both neutralizing antibodies and T-cell responses when compared with spike (S) protein; in addition 71 peptides were identified as helper T-cell epitopes, 34 peptides were identified as CTL epitopes; just top 10 helper T-cell epitopes and CTL epitopes based on maximum HLA binding alleles, can elicit protective cellular immune responses against MERS-CoV were considered as MERS vaccine candidates and they are covering 15 geographic regions \[[@CR19]\].

In this study that consists of two parts reference and modified sequence of both S glycoprotein and E protein, I found that the most common B-cell epitope that passed all B-cell prediction methods \[IEDB prediction tool\] for E protein is YVKFQDS in position 69 and for modified E they are VYVPQQD, YVPQQDS, and PPLPED/PPLPEDV epitopes at positions 68, 69, and 77 sequentially; while for S and modified S, they are DVGPDSV, PDSVKSA, DSVKSAC, PRPIDVS, HTPATDC, AKPSGSV, KPSGSVV, SGTPPQV, GTPPQVY, TPPQVYN, QLSPLEG, YGPLQTP, PRSVRSV, RSVRSVP, SVKSSQS, VKSSQSS, SQSSPII, and SLNTKYV at positions 23, 26, 27, 48, 211, 371, 372, 393, 394, 395, 547, 707, 750, 751, 856, 859 (857 in modified S glycoprotein), and 1202 sequentially, but QVDQLNS and VDQLNSS epitopes at positions 772 and 773 are only found in S glycoprotein, while LTPTSSY, TPTSSYV, PTSSYVD, TSSYVDV, DHGDYYV, YSQDVKQ, ANQYSPC, NQYSPCV, and YYRKQLS epitopes at positions 15, 16, 17, 18, 83, 108, 523, 524, and 543 are only found in modified S glycoprotein; according to my study, I found that the results of S and modified S glycoprotein they are partially agree with the study that was done in Africa city of Technology-Khartoum, Sudan by Badawi et al, \[[@CR16]\] in those epitopes GTPPQVY in position 391--397 and LTPRSVRSVP in position 745--754, may be do you to different numbers of selected MERS-CoV protein sequence.

Prediction of cytotoxic T-lymphocyte epitopes and their interaction with MHC Class I, the results showed ILDYFSYPL was similar according my study, Badwai et al \[[@CR16]\] and Poorinmohammad and Mohabatkar \[[@CR15]\] studies; partially similarity with Iranian study \[[@CR15]\] in LLSGTPPQV, ILATVPHNL, LQMGFGITV, and FSNPTCLIL epitopes were noticed except NLTTITKPL epitope that was absent from my study in S and modified S sequence; FSNPTCLIL represents the only epitope that is found in my study in S and modified S sequence; FSFGVTQEY have a high affinity to bind to many alleles and these findings agree with Badawi et al. \[[@CR16]\] in addition to ITYQGLFPY in my study through S glycoprotein sequence, but still there are differences in the numbers of selected epitopes that reacted with MHC-I which were higher than that in Badawi et al. \[[@CR16]\], while in E protein FIFTVVCAI epitope has a higher allele affinity followed by ITLLVCMAF, IVNFFIFTV, and LVQPALYLY reverse modified E protein; LVQPALSLY epitope has shown high affinity and then followed by LYMTGRSVY, WFIPNFFDF, YMTGRSVYV, ITLLVCTAF, FVQERIGWF, FLTATHLCV, and CMTGFNTLL, the last epitope which is common between E and modified E protein sequences.

Prediction of T-helper cell epitopes and their interactions with MHC Class II showed FNLTLLEPVSISTGS epitope that was considered as the most suitable epitope with a high affinity to 26 alleles in Badawi et al. \[[@CR16]\]; this epitope was actually found in S and modified S sequence of my study, but the difference is that it cannot considered that the most suitable epitope with a high binding affinity to different alleles like in in Badawi et al, \[[@CR16]\] study.

There is no research results related to E protein and modified E and S glycoprotein epitope vaccine instead of partial similarity that I found between S and modified S glycoprotein.

No previous study illustrates S glycoprotein and E protein allergic reactions except the study that were done by Shi J et al. \[[@CR19]\] for N protein, but in this study, S and E protein showed no allergic reaction according to AllerHunter services. Furthermore Shi J et al. \[[@CR19]\] said that, for N protein, the analysis of the surface accessibility of the predicted peptides showed that the maximum surface probability value was 6.971 at amino acid position from 363 to 368 (363KKEKKQ368), but the minimum value of surface probability was 0.074 for 205GIGAVG210 peptides, while in the analysis of the flexibility of the predicted peptides, they showed that the maximum flexibility value was 1.160 at amino acid position from 170 to 176 (167GNSQSSS173) with the minimum value 0.903 for peptides 97RWYFYYT103; in MHC-II the epitope 329LRYSGAIKL337 interacting with 357 HLA-DR alleles was considered the epitope that possesses the maximum number of binding HLA-DR alleles, while 230VKQSQPKVI238 interacting with 94 HLA-DR alleles is the epitope that possesses the minimum number of binding HLA-DR alleles, and also the same occurred with MHC-I; KQLAPRWYF100 had the highest number of binding HLA-A alleles in MHC-I and then followed by 343NYNKWLELL351,72AQNAGYWRR80, and 387RVQGSITQR395 (*see* \[[@CR19]\]) paper for coverage population); in addition to the above, the studies that were done by Sharmin and Islam \[[@CR20]\] showed that WDYPKCDRA was considered as a highly conserved epitope in the RNA directed RNA polymerase of human coronaviruses after applying multiple sequence alignment (MSA) approach for spike (S), membrane (M), enveloped (E), and nucleocapsid (N) protein and replicase polyprotein 1ab to identify which one is highly conserved in all coronavirus strains, followed by using various in silico tools to predict consensus immunogenic and conserved peptide.

Furthermore information that were not shown here are that I used the software below to confirm MHC-II results, and their results partially agree with IEDB MHC-I results and I do not know why. EpiDOCK: Molecular docking---based tool for MHC class II binding prediction (<http://epidock.ddg-pharmfac.net/>), EpiTOP1.0 (<http://www.pharmfac.net/EpiTOP/index.php>), other things that I do not agree with Shi J et al. \[[@CR19]\] when he did alignments for S, E, M... .., with all human coronavirus & said he just found the most common peptide was N protein alone, because when I trying to made alignment for S, M, ORFA1,.., I found some alignments between those proteins and different coronavirus strains and this may be means presence of some common peptide but it still needs more studies.

Conclusions {#Sec63}
-----------

As I mentioned before, software vaccine and drug design became very important in the first and third world countries to avoid wasting resources, time, and efforts; for MERS-CoV vaccine, it is important to design effective vaccine that cannot be protected against MERS-CoV but also the emergence of new strain besides the other human coronavirus especially when MERS-CoV vaccines they are not passed all vaccine design protocols.

In this study I found the following points: Emergence of a new strains may had a minor change in peptide sequence vaccine especially when the selected viruses parts nor longer neither smaller in their length.

In B-cell prediction; mutations can lead to increased numbers of selected epitopes with very few sequence changes noticed, in addition to a large number of shared epitopes between reference and modified sequence; this means mutated sequence has the ability to elicit the same immune response (IR) (response to virus by the same antibodies as in first infections).

Mutations of the virus sequence can change the frequency of allele and peptide numbers eithers through increased or decreased these numbers, beside presences or absences of some new/old alleles or peptides; same alleles had a different peptide sequences and vice versa.

For MHC-II there were not changed in E & modified E protein alleles & their frequencies & also in peptide sequences & their frequencies were noticed, these may be due to short E protein sequence, while for S & modified S glycoprotein there are minor difference in some peptide frequency numbers either by adding/lowering one or two numbers just & same for alleles.

There is an allele similarity between E, S, and modified E and S proteins in MHC-II, besides presence of a tiny difference in S and modified S peptide sequences in MHC-II due to the modification that I was introduced before in S reference sequence.

The absence of very few numbers of peptide sequences from S reference sequence in modified S sequence leads to the presence of a new peptide sequences.

In MHC-I a lot of selected peptide sequences that are represented in S glycoprotein reference sequence are missing from the modified one reverse E protein reference sequence due to presence of additional epitopes in E protein modified sequence.

The presence of arginine in some selected peptide sequence vaccine makes it ineffective, so we need to solve this problem either by replacing it with other amino acid from the same group or by finding another ways that make those epitopes visible for immune system (IS).

The presence of mutated sequence can effect on the coverage population in MHC-II by presence/absence of some countries, with the percentage changes, reverse MHC-I no changes were noticed.
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